var title_f32_0_32768="Povidone iodine: Drug information";
var content_f32_0_32768=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Povidone iodine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29570?source=see_link\">",
"       Povidone iodine (ophthalmic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/35/28213?source=see_link\">",
"       Povidone iodine (topical): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9801 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.170.48.130-B1CD8C1B47-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_0_32768=[""].join("\n");
var outline_f32_0_32768=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29570?source=related_link\">",
"      Povidone iodine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?27/35/28213?source=related_link\">",
"      Povidone iodine (topical): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_0_32769="Dactylitis in psoriatic juvenile idiopathic arthritis PI";
var content_f32_0_32769=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F86794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F86794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 600px\">",
"   <div class=\"ttl\">",
"    Finger and toe swelling in psoriatic arthritis in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 580px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photo A shows swelling of the 2nd and 4th toes. Photo B shows swelling of the thumb and pointer (1st) finger. The medical term for this type of swelling is \"dactylitis.\"",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_0_32769=[""].join("\n");
var outline_f32_0_32769=null;
var title_f32_0_32770="Junctional ectopic rhythm";
var content_f32_0_32770=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F86497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F86497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 610px\">",
"   <div class=\"ttl\">",
"    Junctional ectopic rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 590px; height: 135px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this tracing of junctional ectopic rhythm, the QRS complexes are narrow and have a rate faster than the P waves. This is an example of atrioventricular dissociation. No retrograde P waves are seen since there is retrograde VA block.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_0_32770=[""].join("\n");
var outline_f32_0_32770=null;
var title_f32_0_32771="Nystatin and triamcinolone: Patient drug information";
var content_f32_0_32771=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nystatin and triamcinolone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/37/26195?source=see_link\">",
"     see \"Nystatin and triamcinolone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691491",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat yeast infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to nystatin, triamcinolone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698702",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If the yeast infection keeps coming back.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10919 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-F0BCE44B44-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_0_32771=[""].join("\n");
var outline_f32_0_32771=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013449\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013448\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013453\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013454\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013456\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013451\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013452\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013457\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013458\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/37/26195?source=related_link\">",
"      Nystatin and triamcinolone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_0_32772="Subperiosteal abscess MRI";
var content_f32_0_32772=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance image distal femoral osteomyelitis and subperiosteal abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 584px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial (A) and coronal (B) magnetic resonance images (post gadolinium infusion) of a 7-year-old with distal femoral osteomyelitis and subperiosteal abscess. The abscess is posterior on the axial view (arrow) and medial to the distal femur on the coronal view (arrow). The pus is dark and surrounded by an enhancing rim.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Phillips, MD, Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_0_32772=[""].join("\n");
var outline_f32_0_32772=null;
var title_f32_0_32773="Flucytosine: Drug information";
var content_f32_0_32773=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Flucytosine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/22/15717?source=see_link\">",
"    see \"Flucytosine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/46/27365?source=see_link\">",
"    see \"Flucytosine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F171786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ancobon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F171821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antifungal Agent, Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F171790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Usual dosage ranges:",
"     </b>",
"     Oral: 50-150 mg/kg/day in divided doses every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Endocarditis:",
"     </b>",
"     Oral: 100 mg/kg daily in 3 or 4 divided doses (with amphotericin B) for at least 4-6 weeks after valve replacement (Gould, 2012; Pappas, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Meningoencephalitis, cryptococcal:",
"     </b>",
"     Induction: 25 mg/kg/dose (with amphotericin B) every 6 hours for at least 4 weeks, or if HIV-infected at least 2 weeks; if clinical improvement, may discontinue both amphotericin and flucytosine and follow with an extended course of fluconazole (Perfect, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F171809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/46/27365?source=see_link\">",
"      see \"Flucytosine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Unlabeled use. Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F171791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F171792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (",
"     <b>",
"      Note:",
"     </b>",
"     Manufacturer recommends dose reduction); however, the following adjustments have been recommended (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults (based upon dosing of 37.5 mg/kg every 6 hours):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: 37.5 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: 37.5 mg/kg every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: 37.5 mg/kg every 24-48 hours, but monitor drug concentrations frequently",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hemodialysis: Dialyzable (50% to 100%); administer dose posthemodialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Peritoneal dialysis: 0.5-1 g every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Continuous renal replacement therapy: 37.5 mg/kg every 12-24 hours (monitor serum concentrations and adjust)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children (based upon dosing of 100-150 mg/kg every 6 hours):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: 25-37.5 mg/kg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-29 mL/minute: 25-37.5 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: 25-37.5 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hemodialysis: 25-37.5 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Peritoneal dialysis: 25-37.5 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Continuous renal replacement therapy: 25-37.5 mg/kg every 8 hours (monitor serum concentrations)",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15881448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F171760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ancobon&reg;: 250 mg, 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F171744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F171765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer around-the-clock to promote less variation in peak and trough serum levels. To avoid nausea and vomiting, administer a few capsules at a time over 15 minutes until full dose is taken.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F171764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive treatment of systemic fungal infections  (eg, septicemia, endocarditis, UTI, meningitis, or pulmonary) caused by susceptible strains of",
"     <i>",
"      Candida",
"     </i>",
"     or",
"     <i>",
"      Cryptococcus",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F171828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flucytosine may be confused with fluorouracil",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ancobon&reg; may be confused with Oncovin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F171819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrest, myocardial toxicity, ventricular dysfunction, chest pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, confusion, fatigue, hallucinations, headache, parkinsonism, psychosis, pyrexia, sedation, seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash, photosensitivity, pruritus, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, duodenal ulcer, enterocolitis, hemorrhage, nausea, ulcerative colitis, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, anemia, aplastic anemia, bone marrow aplasia, eosinophilia, leukopenia, pancytopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Acute hepatic injury, bilirubin increased, hepatic dysfunction, jaundice, liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, peripheral neuropathy, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Azotemia, BUN increased, crystalluria, renal failure, serum creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, respiratory arrest",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F171769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to flucytosine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F171748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic disease: Use with caution in patients with bone marrow depression, hematologic disease or who have been treated with radiation or drugs that suppress the bone marrow; bone marrow toxicity may be irreversible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; hepatotoxicity may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment:",
"     <b>",
"      [U.S. Boxed Warning]: Use with extreme caution in patients with renal dysfunction;",
"     </b>",
"     dosage adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monitoring:",
"     <b>",
"      [U.S. Boxed Warning]: Closely monitor hematologic, renal, and hepatic status.",
"     </b>",
"     Hepatotoxicity and bone marrow toxicity appear to be dose related; monitor levels closely and adjust dose accordingly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monotherapy: Avoid use as monotherapy; resistance rapidly develops.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F171753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: May enhance the adverse/toxic effect of Flucytosine. This may be related to the adverse effects of amphotericin B on renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cytarabine (Conventional): May diminish the therapeutic effect of Flucytosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saccharomyces boulardii: Antifungal Agents may diminish the therapeutic effect of Saccharomyces boulardii.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F171782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Food decreases the rate, but not the extent of absorption.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F171756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F171772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal reproduction studies. Flucytosine is metabolized to fluorouracil which may cause adverse events if administered during pregnancy; refer to the fluorouracil monograph for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F171797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16355155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if flucytosine is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F171771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Ancobon Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $5893.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $11403.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Flucytosine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $2316.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $4482.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F171758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pretreatment: Electrolytes (especially potassium), CBC with differential, BUN, renal function, blood culture",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     During treatment: CBC with differential, and LFTs (eg, alkaline phosphatase, AST/ALT) frequently, serum flucytosine concentration, renal function",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F171761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic: Trough: 25-50 mcg/mL; peak: 50-100 mcg/mL; peak levels should not exceed 100 mcg/mL to avoid bone marrow toxicity and hepatotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Trough: Draw just prior to dose administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak: Draw 2 hours after an oral dose administration",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alcobon (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, NZ, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Ancobon (HK);",
"     </li>",
"     <li>",
"      Ancotil (AE, AT, AU, BG, BH, BR, CH, CY, CZ, DE, DK, EG, FR, GB, GR, HR, IE, IL, IQ, IR, IT, JO, KW, LB, LY, NL, NO, OM, PL, QA, SA, SE, SG, SY, YE);",
"     </li>",
"     <li>",
"      Ancotyl (RU);",
"     </li>",
"     <li>",
"      Cocol (JP);",
"     </li>",
"     <li>",
"      Flusine (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F171747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Penetrates fungal cells and is converted to fluorouracil which competes with uracil interfering with fungal RNA and protein synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F171768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 78% to 89%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Into CSF, aqueous humor, joints, peritoneal fluid; V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.6 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 3% to 4%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Minimally hepatic; deaminated, possibly via gut bacteria, to 5-fluorouracil",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Normal renal function: 2-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anuria: 85 hours (range: 30-250)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     End stage renal disease: 75-200 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: ~1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&gt;90% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians, 2007, 70, 158.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/0/32773/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults:  A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2012, 67(2):269-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/0/32773/abstract-text/22086858/pubmed\" id=\"22086858\" target=\"_blank\">",
"        22086858",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lau AH and Kronfol NO, &ldquo;Elimination of Flucytosine by Continuous Hemofiltration,&rdquo;",
"      <i>",
"       Am J Nephrol",
"      </i>",
"      , 1995, 15(4):327-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/0/32773/abstract-text/7573192/pubmed\" id=\"7573192\" target=\"_blank\">",
"        7573192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lyman CA and Walsh TJ, &ldquo;Systemically Administered Antifungal Agents. A Review of Their Clinical Pharmacology and Therapeutic Applications,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1992, 44(1):9-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/0/32773/abstract-text/1379913/pubmed\" id=\"1379913\" target=\"_blank\">",
"        1379913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pappas PG, Kauffman CA, Andes D, et al, \"Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Di",
"      </i>",
"      s, 2009, 48(5):503-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/0/32773/abstract-text/19191635/pubmed\" id=\"19191635\" target=\"_blank\">",
"        19191635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Patel R, &ldquo;Antifungal Agents. Part I. Amphotericin B Preparations and Flucytosine,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1998, 73(12):1205-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/0/32773/abstract-text/9868423/pubmed\" id=\"9868423\" target=\"_blank\">",
"        9868423",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perfect JR, Dismukes WE, Dromer F, et al, \"Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2010, 50(3):291-322.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/0/32773/abstract-text/20047480/pubmed\" id=\"20047480\" target=\"_blank\">",
"        20047480",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saag MS, Graybill RJ, Larsen RA, et al, &ldquo;Practice Guidelines for the Management of Cryptococcal Disease. Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2000, 30(4):710-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/0/32773/abstract-text/10770733/pubmed\" id=\"10770733\" target=\"_blank\">",
"        10770733",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vermes A, Guchelaar H, and Dankert J, &ldquo;Flucytosine: A Review of its Pharmacology, Clinical Indications, Pharmacokinetics, Toxicity and Drug Interactions,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2000, 46(2):171-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/0/32773/abstract-text/10933638/pubmed\" id=\"10933638\" target=\"_blank\">",
"        10933638",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8451 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.69.132.100-BE5EBB4FC7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_0_32773=[""].join("\n");
var outline_f32_0_32773=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708774\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171786\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171821\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171790\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171809\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171791\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171792\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881448\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171760\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171744\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171765\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171764\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171828\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171819\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171769\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171748\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299342\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171753\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171782\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171756\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171772\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171797\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16355155\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171771\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171758\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171761\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038617\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171747\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171768\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8451\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8451|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/22/15717?source=related_link\">",
"      Flucytosine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/46/27365?source=related_link\">",
"      Flucytosine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_0_32774="Paricalcitol: Drug information";
var content_f32_0_32774=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Paricalcitol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/36/17989?source=see_link\">",
"    see \"Paricalcitol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/33/31254?source=see_link\">",
"    see \"Paricalcitol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F206463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zemplar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F206464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zemplar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F206482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vitamin D Analog",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F206466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     In stage 3-5 CKD maintain  Ca x P &lt;55 mg",
"     <sup>",
"      2",
"     </sup>",
"     /dL",
"     <sup>",
"      2",
"     </sup>",
"     , reduce or interrupt dosing if recommended calcium phosphorus product (Ca x P) is exceeded or hypercalcemia is observed (K/DOQI Clinical Practice Guidelines, 2003).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Secondary hyperparathyroidism associated with chronic renal failure (stage 5 CKD):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: 0.04-0.1 mcg/kg (2.8-7 mcg) given as a bolus dose no more frequently than every other day at any time during dialysis; dose may be increased by 2-4 mcg every 2-4 weeks; doses as high as 0.24 mcg/kg (16.8 mcg) have been administered safely;  the dose of paricalcitol should be adjusted based on serum intact  PTH (iPTH) levels, as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Same or increasing iPTH level: Increase paricalcitol dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     iPTH level decreased by &lt;30%: Increase paricalcitol dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     iPTH level decreased by &gt;30% and &lt;60%: Maintain paricalcitol dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     iPTH level decrease by &gt;60%: Decrease paricalcitol dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     iPTH level 1.5-3 times upper limit of normal: Maintain paricalcitol dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Initial dose, in mcg, based on baseline iPTH level divided by 80. Administered 3 times weekly, no more frequently than every other day.",
"     <b>",
"      Note:",
"     </b>",
"     To reduce the risk of hypercalcemia initiate only after baseline serum calcium has been adjusted to &le;9.5 mg/dL.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dose titration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Titration dose (mcg) = Most recent iPTH level (pg/mL) divided by 80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     In situations where monitoring of iPTH, calcium, and phosphorus occurs less frequently than once per week, a more modest initial and dose titration rate may be warranted:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Modest titration dose (mcg) = Most recent iPTH level (pg/mL) divided by 100",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Dosage adjustment for hypercalcemia or elevated Ca x P:",
"     </i>",
"     Decrease calculated dose by 2-4 mcg. If further adjustment is required, dose should be reduced or interrupted until these parameters are normalized. If applicable, phosphate binder dosing may also be adjusted or withheld, or switch to a noncalcium-based phosphate binder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Secondary hyperparathyroidism associated with stage 3 and 4 CKD:",
"     </b>",
"     Adults: Oral: Initial dose based on baseline serum iPTH:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     iPTH &le;500 pg/mL: 1 mcg/day or 2 mcg 3 times/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     iPTH &gt;500 pg/mL: 2 mcg/day or 4 mcg 3 times/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Dosage adjustment based on iPTH level relative to baseline",
"     </i>",
"     , adjust dose at 2-4 week intervals:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     iPTH same or increased: Increase paricalcitol dose by 1 mcg/day or 2 mcg 3 times/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     iPTH decreased by &lt;30%: Increase paricalcitol dose by 1 mcg/day or 2 mcg 3 times/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     iPTH decreased by &ge;30% and &le;60%: Maintain paricalcitol dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     iPTH decreased by &gt;60%: Decrease paricalcitol dose by 1 mcg/day* or 2 mcg 3 times/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     iPTH &lt;60 pg/mL: Decrease paricalcitol dose by 1 mcg/day* or 2 mcg 3 times/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     *If patient is taking the lowest dose on a once-daily regimen, but further dose reduction is needed, decrease dose to 1 mcg 3 times/week. If further dose reduction is required, withhold drug as needed and restart at a lower dose. If applicable, calcium-phosphate binder dosing may also be adjusted or withheld, or switch to noncalcium-based binder.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F206476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/33/31254?source=see_link\">",
"      see \"Paricalcitol: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Secondary hyperparathyroidism associated with chronic renal failure (stage 5 CKD):",
"     </b>",
"     I.V.: Children &ge;5 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F206467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F206468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F206469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate hepatic impairment: No dosage adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Severe hepatic impairment: Use has not been evaluated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F206452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, soft gelatin, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zemplar&reg;: 1 mcg, 2 mcg, 4 mcg [contains coconut oil (may have trace amounts), ethanol, palm kernel oil (may have trace amounts)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zemplar&reg;: 2 mcg/mL (1 mL); 5 mcg/mL (1 mL, 2 mL) [contains ethanol 20%, propylene glycol 30%]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F206438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F730141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: May be administered with or without food. With the 3 times/week dosing schedule, doses should not be given more frequently than every other day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.:  Administered as a bolus dose at anytime during dialysis. Doses should not be administered more often than every other day.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F206454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Prevention and treatment of secondary hyperparathyroidism associated with stage 5 chronic kidney disease (CKD)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Prevention and treatment of secondary hyperparathyroidism associated with stage 3 and 4 CKD and stage 5 CKD patients on hemodialysis or peritoneal dialysis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7297725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound alike/look alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Paricalcitol may be confused with calcitriol",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zemplar&reg; may be confused with zaleplon, Zelapar&reg;, zolpidem, ZyPREXA&reg; Zydis&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F206480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     Gastrointestinal: Nausea (5% to 13%), diarrhea (7% to 12%)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     Miscellaneous: Infection (bacterial, fungal, viral: 3% to 15%)",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Edema (7%), hypertension (7%), hypervolemia (5%), hypotension (5%), palpitation (3%), chest pain (3%), peripheral edema (3%), syncope (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Pain (8%), dizziness (5% to 7%), chills (5%), insomnia (5%), lightheadedness (5%), vertigo (5%), fever (3% to 5%), headache (3% to 5%), anxiety (3%), depression (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Rash (6%), bruising (3%), skin ulcer (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration (3%), hypoglycemia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (5% to 8%), GI bleeding (5%), constipation (4% to 5%), abdominal pain (4%), dyspepsia (3%), xerostomia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthritis (5%), weakness (3% to 5%), back pain (4%), leg cramps (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Renal: Uremia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Pneumonia (5%), rhinitis (5%), oropharyngeal pain (4%), bronchitis (3%), cough (3%), sinusitis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction (6%), flu-like syndrome (5%), peritonitis (5%), sepsis (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     &lt;2% (Limited to important or life-threatening): Agitation, anemia, angioedema (including laryngeal edema), arrhythmia, atrial flutter, bleeding time prolonged, breast cancer, cardiac arrest, cerebrovascular accident, chest discomfort, confusional state, conjunctivitis, delirium, dysphagia, dyspnea, erectile dysfunction, gait disturbance, gastritis, gastroesophageal reflux, glaucoma, hepatic enzyme (abnormal), hirsutism, hypercalciuria, hyper-/hypocalcemia, hyper-/hypoparathyroidism, hyperkalemia, hyperphosphatemia, injection site extravasation, injection site pain, intestinal ischemia, lymphadenopathy, myalgia, myoclonus, nasopharyngitis, night sweats, ocular hyperemia, oral edema, orthopnea, paresthesia, pruritus, pulmonary edema, rectal hemorrhage, skin burning sensation, taste perversion (metallic), upper respiratory tract infection, urticaria, vaginal infection, weight loss, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F206457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to paricalcitol or any component of the formulation; patients with evidence of vitamin D toxicity; hypercalcemia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F206442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Excessive vitamin D: Excessive vitamin D administration may lead to over suppression of PTH, progressive or acute hypercalcemia, hypercalciuria, hyperphosphatemia and adynamic bone disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercalcemia: Progressive and/or acute hypercalcemia may increase risk of cardiac arrhythmias and seizures; chronic hypercalcemia may lead to generalized vascular and other soft-tissue calcification. Phosphate and vitamin D (and its derivatives) should be withheld during therapy to avoid hypercalcemia. Risk of hypercalcemia may be increased by concomitant use of calcium-containing supplements and/or medications that increase serum calcium (eg, thiazide diuretics).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aluminum: Avoid regular administration to prevent aluminum overload and toxicity. Dialysate concentration of aluminum should be maintained at &lt;10 mcg/L.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac glycosides: Use with caution in patients taking cardiac glycosides; digitalis toxicity is potentiated by hypercalcemia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F730134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F206447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Paricalcitol may enhance the adverse/toxic effect of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mineral Oil: May decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs. Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orlistat: May decrease the serum concentration of Paricalcitol. Management: Monitor clinical response to paricalcitol closely when used with orlistat.  When this combination must be used, consider administering paricalcitol at least 2 hours before or after the administration of orlistat.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F206448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F730133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate and well-controlled studies in pregnant women; use during pregnancy only if potential benefit to mother outweighs possible risk to fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F206472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F730140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food. Some products may contain coconut or palm kernel oil.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Zemplar Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mcg (30): $369.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mcg (30): $739.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mcg (30): $1478.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Zemplar Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mcg/mL (1 mL): $7.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mcg/mL (1 mL): $18.18",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F206450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Signs and symptoms of vitamin D intoxication",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Serum calcium and phosphorus (closely monitor levels during dosage titration and after initiation of a strong CYP3A4 inhibitor):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     I.V.: Twice weekly during initial phase, then at least monthly once dose established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Oral: At least every 2 weeks for 3 months or following dose adjustment, then monthly for 3 months, then every 3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Serum or plasma intact PTH (iPTH):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     I.V.: Every 3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Oral: At least every 2 weeks for 3 months or following dose adjustment, then monthly for 3 months, then every 3 months",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F730135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corrected total serum calcium (K/DOQI, 2003): CKD stages 3 and 4: 8.4-10.2 mg/dL (2.1-2.6 mmol/L); CKD stage 5: 8.4-9.5 mg/dL (2.1-2.37 mmol/L); KDIGO guidelines recommend maintaining normal ranges for all stages of CKD (3-5D) (KDIGO, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphorus (K/DOQI, 2003):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CKD stages 3 and 4: 2.7-4.6 mg/dL (0.87-1.48 mmol/L) (adults); maintain within age-appropriate limits (children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CKD stage 5 (including those treated with dialysis): 3.5-5.5 mg/dL (1.13-1.78 mmol/L) (children &gt;12 years and adults); 4-6 mg/dL (1.29-1.94 mmol/L) (children 1-12 years)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     KDIGO guidelines recommend maintaining normal ranges for CKD stages 3-5 and lowering elevated phosphorus levels toward the normal range for CKD stage 5D (KDIGO, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Serum calcium-phosphorus product (K/DOQI, 2003): CKD stage 3-5: &lt;55 mg",
"     <sup>",
"      2",
"     </sup>",
"     /dL",
"     <sup>",
"      2",
"     </sup>",
"     (children &gt;12 years and adults); &lt;65 mg",
"     <sup>",
"      2",
"     </sup>",
"     /dL",
"     <sup>",
"      2",
"     </sup>",
"     (children &le;12 years)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     PTH: Whole molecule, immunochemiluminometric assay (ICMA): 1.0-5.2 pmol/L; whole molecule, radioimmunoassay (RIA): 10.0-65.0 pg/mL; whole molecule, immunoradiometric, double antibody (IRMA): 1.0-6.0 pmol/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Target ranges by stage of chronic kidney disease (KDIGO, 2009): CKD stage 3-5: Optimal iPTH is unknown; maintain normal range (assay-dependent); CKD stage 5D: Maintain iPTH within 2-9 times the upper limit of normal for the assay used",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F206458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Zemplar (AR, AT, AU, BG, CH, CN, CO, CZ, DE, DK, EC, EE, FI, GB, GR, HK, HN, IE, IL, IT, KP, MX, MY, NL, NO, PE, PT, SE, SG, TW, UY, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F206441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreased renal conversion of vitamin D to its primary active metabolite (1,25-hydroxyvitamin D) in chronic renal failure leads to reduced activation of vitamin D receptor (VDR), which subsequently removes inhibitory suppression of parathyroid hormone (PTH) release; increased serum PTH (secondary hyperparathyroidism) reduces calcium excretion and enhances bone resorption. Paricalcitol is a synthetic vitamin D analog which binds to and activates the VDR in kidney, parathyroid gland, intestine and bone, thus reducing PTH levels and improving calcium and phosphate homeostasis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F206456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Healthy subjects: Oral: 34 L; I.V.: 24 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stage 3 and 4 CKD: Oral: 44-46 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stage 5 CKD: Oral: 38-49 L; I.V.: 31-35 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hydroxylation and glucuronidation via hepatic and nonhepatic enzymes, including CYP24, CYP3A4, UGT1A4; forms metabolites (at least one active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 72% to 86% in healthy subjects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Healthy subjects: Oral: 4-6 hours; I.V.: 5-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Stage 3 and 4 CKD: Oral: 14-20 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Stage 5 CKD: Oral: 14-20 hours; I.V.: 14-15 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 3 hours: Delayed by food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Healthy subjects: Feces (oral: 70%; I.V.: 63%); urine (oral: 18%, I.V.: 19%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Children With Chronic Kidney Disease.&rdquo; Available at  file://www.kidney.org/professionals/KDOQI/guidelines_pedbone/index.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Guideline 1. Evaluation of Calcium and Phosphorus Metabolism.&rdquo; Available at  file://www.kidney.org/professionals/KDOQI/guidelines_bone/Guide1.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Guideline 3. Evaluation of Serum Phosphorus Levels.&rdquo; Available at file://www.kidney.org/professionals/KDOQI/guidelines_bone/Guide3.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification, Part 4. Definition and Classification of Stages of Chronic Kidney Disease.&rdquo; Available at file://www.kidney.org/professionals/KDOQI/guidelines_ckd/p4_class.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, \"KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD),\"",
"      <i>",
"       Kidney Int Suppl",
"      </i>",
"      , 2009, 76(S113):1-130.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/0/32774/abstract-text/19644521/pubmed\" id=\"19644521\" target=\"_blank\">",
"        19644521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10197 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-593C6D74E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_0_32774=[""].join("\n");
var outline_f32_0_32774=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206463\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206464\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206482\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206466\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206476\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206467\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206468\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206469\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206452\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206438\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F730141\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206454\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7297725\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206480\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206457\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206442\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F730134\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206447\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206448\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F730133\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206472\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F730140\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422271\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206450\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F730135\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206458\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206441\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206456\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10197\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10197|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/36/17989?source=related_link\">",
"      Paricalcitol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/33/31254?source=related_link\">",
"      Paricalcitol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_0_32775="Pseudoporphyria immunofluorescence";
var content_f32_0_32775=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Direct immunofluorescence findings in pseudoporphyria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Direct immunofluorescence shows deposition of IgG at the dermoepidermal junction and in the dermal vessels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Grant Anhalt, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_0_32775=[""].join("\n");
var outline_f32_0_32775=null;
var title_f32_0_32776="Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis";
var content_f32_0_32776=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/0/32776/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/0/32776/contributors\">",
"     David Baldwin, DM FRCPsych",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/0/32776/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/0/32776/contributors\">",
"     Murray B Stein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/0/32776/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/0/32776/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/0/32776/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H448541396\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generalized anxiety disorder (GAD) is characterized by excessive and persistent worrying that is hard to control, causes significant distress or impairment, and occurs on more days than not for at least six months. Other features include psychological symptoms of anxiety, such as apprehensiveness and irritability, and physical (or somatic) symptoms of anxiety, such as increased fatigue and muscular tension.",
"   </p>",
"   <p>",
"    Effective treatments for generalized anxiety disorder include psychological interventions such as cognitive-behavioral therapy, and medications including selective serotonin reuptake inhibitors.",
"   </p>",
"   <p>",
"    This topic addresses the epidemiology, pathogenesis, clinical manifestations, and diagnosis of generalized anxiety disorder. Pharmacotherapy and psychotherapy for generalized anxiety disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/38/2665?source=see_link\">",
"     \"Pharmacotherapy for generalized anxiety disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/1/20505?source=see_link\">",
"     \"Psychotherapy for generalized anxiety disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H448541403\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generalized anxiety disorder (GAD) is common in both community and clinical settings. Epidemiologic studies of nationally representative samples in the United States (US) have found a lifetime prevalence of GAD of 5.1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/1,2\">",
"     1,2",
"    </a>",
"    ] to 11.9 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/3\">",
"     3",
"    </a>",
"    ]. A review of epidemiological studies in Europe found a 12-month prevalence of 1.7 to 3.4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/4\">",
"     4",
"    </a>",
"    ], and a lifetime prevalence of 4.3 to 5.9 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GAD is one of the most common mental disorders in primary care settings and is associated with increased use of health services [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/6\">",
"     6",
"    </a>",
"    ]. In a study of adult primary care patients in four Nordic countries, the rates of GAD were 4.1 to 6.0 percent among men, and 3.7 to 7.1 percent among women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The disorder is approximately twice as common in women as it is in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. GAD is probably the most common anxiety disorder among the elderly population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/4,8\">",
"     4,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H343899757\">",
"    <span class=\"h2\">",
"     Comorbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comorbidity with major depression or other anxiety disorders has been observed in the majority of cases of GAD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/4\">",
"     4",
"    </a>",
"    ]. In a nationally representative survey of US adults, 66 percent of individuals with current GAD had at least one concurrent disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/1\">",
"     1",
"    </a>",
"    ]. Individual disorders found to co-occur in people with GAD (rates over the previous 30 days and lifetime) included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Social phobia &mdash; 23.2 and 34.4 percent",
"     </li>",
"     <li>",
"      Specific phobia &mdash; 24.5 and 35.1 percent",
"     </li>",
"     <li>",
"      Panic disorder &mdash; 22.6 and 23.5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    GAD may also be associated with increased rates of substance abuse, posttraumatic stress disorder, and obsessive-compulsive disorder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/38/37481?source=see_link\">",
"     \"Unipolar depression in adults: Epidemiology, pathogenesis, and neurobiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/44/44744?source=see_link\">",
"     \"Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/24/22921?source=see_link\">",
"     \"Specific phobia in adults: Epidemiology, clinical manifestations, course and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44713?source=see_link\">",
"     \"Panic disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/22/2409?source=see_link\">",
"     \"Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27352?source=see_link\">",
"     \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36564?source=see_link\">",
"     \"Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with comorbid major depression and GAD tended to have a more severe and prolonged course of illness and greater functional impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/10\">",
"     10",
"    </a>",
"    ]. The presence of comorbid major depressive episodes is associated with a poorer prognosis in patients with GAD. The NCS follow-up study found that patients with comorbid GAD and major depression were significantly more likely to fulfil criteria for GAD ten years later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GAD is common among patients with &lsquo;medically unexplained&rsquo; chronic pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/11\">",
"     11",
"    </a>",
"    ] and with chronic physical illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H448541455\">",
"     'Course'",
"    </a>",
"    below.).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H448541410\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H448541418\">",
"    <span class=\"h2\">",
"     Biological factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic factors appear to predispose individuals to the development of generalized anxiety disorder (GAD), though data from twin studies have been inconsistent. GAD shares a common heritability with major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/13\">",
"     13",
"    </a>",
"    ] and with the personality trait of &ldquo;neuroticism&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The serotonin transporter gene-linked polymorphic region SS genotype",
"    <span class=\"nowrap\">",
"     (short/short)",
"    </span>",
"    has been found to be more frequent in patients with GAD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/16\">",
"     16",
"    </a>",
"    ]. Variations in two sub-types of the glutamic acid decarboxylase gene may increase individual susceptibility to anxiety disorders, including GAD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Investigations of potential disturbances in the principal neurotransmitters norepinephrine, 5-hydroxtryptamine (5-HT, serotonin) and gamma aminobutyric acid (GABA) in GAD have tended to be small, inconsistent, or unreplicated. Early studies suggested the levels of the norepinephrine metabolites 3-methoxy-4-hydroxyphenylgycol and vanillylmandelic acid are increased in patients with GAD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The growth hormone response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    challenge has been found to be blunted, suggesting decreased postsynaptic alpha-2 adrenergic receptor sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/21\">",
"     21",
"    </a>",
"    ]. Elevated urinary levels of the serotonin metabolite 5-hydroxyindoleacetic acid are associated with greater anxiety severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/20\">",
"     20",
"    </a>",
"    ]. Benzodiazepine binding sites on platelets and lymphocytes are reduced in density in patients with GAD, but increase in density after administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H448541426\">",
"    <span class=\"h2\">",
"     Neuropsychological factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study of positron emission tomography (PET) scans in patients with GAD demonstrated a relative increase in glucose metabolism in parts of the occipital, right posterior temporal lobe, inferior gyrus, cerebellum and right frontal gyrus, and an absolute decrease in the basal ganglia: benzodiazepine administration was associated with decreases in absolute metabolic rates for cortical surface, limbic system and basal ganglia, but was not associated with normalization of patterns of glucose metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/24\">",
"     24",
"    </a>",
"    ]. A functional MRI study found increased post cue anticipatory activity bilaterally in the dorsal amygdala, after cues indicating forthcoming neutral and aversive pictures, providing evidence of overall enhanced anticipatory emotional responsiveness in GAD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Investigations of the processing of emotional information suggest that GAD may be associated with specific biases for mood-congruent information [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/26\">",
"     26",
"    </a>",
"    ]. Patients with GAD have been found to allocate extensive attentional resources to threatening stimuli, detect &lsquo;threats&rsquo; rapidly and effectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/27\">",
"     27",
"    </a>",
"    ], and misinterpret ambiguous information as being threatening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/28\">",
"     28",
"    </a>",
"    ]. These biases diminished with successful treatment with cognitive-behavioral therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/29\">",
"     29",
"    </a>",
"    ] or a selective serotonin reuptake inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H448541433\">",
"    <span class=\"h2\">",
"     Developmental and personality factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;GAD in adult life is associated with a higher-than-average number of traumatic experiences and other undesirable life events in childhood, compared to individuals without GAD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/31\">",
"     31",
"    </a>",
"    ]. GAD is more likely to occur in people with &lsquo;behavioral inhibition&rsquo;, which is the tendency to be timid and shy in novel situations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/32\">",
"     32",
"    </a>",
"    ]. The personality trait of &lsquo;neuroticism&rsquo; (or negative affectivity) is associated with comorbid GAD and major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H448541441\">",
"    <span class=\"h2\">",
"     Cognitive origins of excessive worrying",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many explanations of the origin and persistence of the excessive and pervasive worrying that characterize GAD have been proposed. As examples, affected individuals may:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Constantly scan the environment for cues of threat [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/35\">",
"       35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Develop worrying in an attempt to solve problems [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/36\">",
"       36",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Use worrying to avoid the fear response [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/37\">",
"       37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Have intolerance of uncertainty or ambiguity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/38\">",
"       38",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Worry about the uncontrollability and presumed dangerous consequences of worrying [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H448541448\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although excessive and persistent worrying is widely regarded as the pathognomic feature of generalized anxiety disorder (GAD), most patients present with other symptoms relating to hyperarousal, autonomic hyperactivity and motor tension. Many complain of poor sleep, fatigue and difficulty relaxing. Headaches and pain in the neck, shoulders, and back are commonly reported. It is common for patients with these symptoms to present to health professionals repeatedly, with pressing but long-standing concerns that prove to be medically unexplained.",
"   </p>",
"   <p>",
"    The nature of excessive and persistent worrying has not been investigated extensively. Individuals with GAD have reported a greater number of worries, but were found to share the same concerns about health, family and interpersonal relationships, work and finances as non-anxious controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/40\">",
"     40",
"    </a>",
"    ]. Individuals with GAD have been distinguished from controls, and from patients with other anxiety disorders, by having greater worry over minor matters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/40\">",
"     40",
"    </a>",
"    ]. Patients with GAD typically respond positively to the question, &ldquo;Do you worry excessively about minor matters?&rdquo;, while a negative response effectively rules out the diagnosis of GAD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H448541455\">",
"    <span class=\"h1\">",
"     COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generalized anxiety disorder (GAD) is considered to be a potentially chronic illness, fluctuating in symptom severity over time. Longitudinal studies in treatment-seeking patients generally provide evidence for a prolonged and fluctuating course of illness. A prospective study of 179 patients with generalized anxiety disorder (DSM-III-R) in the US found that approximately 60 percent of patients recovered over 12 years (ie, had no more than residual symptoms for eight consecutive weeks), but around one-half of recovered patients subsequently relapsed during the 12 year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/42\">",
"     42",
"    </a>",
"    ] The decline in mean anxiety symptom severity in the patients with GAD was only modest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of people with GAD in community samples suggest a better prognosis than studies of clinical populations. A 22-year follow up study of 105 individuals meeting DSM-III criteria for GAD found that less than 20 percent had persistent GAD (defined by the presence of daily symptoms over the previous 12 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GAD typically has a gradual evolution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/45\">",
"     45",
"    </a>",
"    ] and an onset of the full syndromal disorder that is later than that seen with some other anxiety disorders, though sub-syndromal anxiety symptoms are common before the age of 20 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/44\">",
"     44",
"    </a>",
"    ]. Patients with an early age of onset tend to have a more protracted course and present with comorbid depression or other disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/46\">",
"     46",
"    </a>",
"    ]. Late-onset GAD usually starts abruptly, and is associated with clearly identifiable stressors.",
"   </p>",
"   <p>",
"    GAD is associated with a significant degree of functional impairment, similar to that with major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GAD and, in particular, worrying have been associated with poor cardiovascular health and with coronary heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/49\">",
"     49",
"    </a>",
"    ] Conclusions drawn from studies of this relationship include: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Excessive worry has been associated with diminished heart rate variability and elevated heart rate",
"     </li>",
"     <li>",
"      Worrying and GAD have been commonly associated with increased blood pressure, diagnosed hypertension, and antihypertensive use in both disease-free patients and those with coronary heart disease",
"     </li>",
"     <li>",
"      Greater severity of worry has been associated with higher rates of fatal and nonfatal coronary heart disease, independent of the presence or severity of depression",
"     </li>",
"     <li>",
"      No evidence has been found to support the contention that worry might be beneficial for health promoting behaviors",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H601612474\">",
"    <span class=\"h1\">",
"     ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychiatric assessment of a patient with possible generalized anxiety disorder (GAD) should include a careful history and evaluation for symptoms of GAD and other psychiatric disorders. (See",
"    <a class=\"local\" href=\"#H448541476\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H343899757\">",
"     'Comorbidity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients who have findings suggesting a possible physical cause of anxiety symptoms &mdash; for example, patients with late-onset anxiety, with weight loss, or with cognitive impairment &mdash; should receive a physical exam and laboratory studies consistent with physical findings (eg, complete blood count, chemistry panel, serum thyrotropin (TSH), urinalysis, electrocardiogram [in patients over 40 with chest pain or palpitations], or urine or serum toxicology analysis for drugs or medications) [",
"    <a class=\"external\" href=\"file://www.uptodate.com/contents/generalized-anxiety-disorder-epidemiology-clinical-manifestations-and-diagnosis/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other components of a psychiatric evaluation that should be emphasized include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A substance abuse history that includes alcohol, prescription drugs, caffeine, and nicotine",
"     </li>",
"     <li>",
"      A medical history that focuses on possible contributory factors relating to current medical disorders or medication side effects",
"     </li>",
"     <li>",
"      A family psychiatric history",
"     </li>",
"     <li>",
"      A social history that screens for stressful life events and past sexual, physical and emotional abuse, or emotional neglect",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H601612593\">",
"    <span class=\"h2\">",
"     Screening instrument",
"    </span>",
"    &nbsp;&mdash;&nbsp;The generalized anxiety disorder seven-item (GAD-7) scale can be used to screen for GAD in primary care. It has been found to have acceptable reliability and criterion, construct, factorial and procedural validity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/50\">",
"     50",
"    </a>",
"    ]. The GAD-7 has been found to be sensitive to change and can be used to monitor symptom severity over time (",
"    <a class=\"graphic graphic_table graphicRef77755 \" href=\"mobipreview.htm?31/30/32236\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H601612600\">",
"    <span class=\"h2\">",
"     Symptom severity assessment instrument",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Hospital Anxiety and Depression Scale (HADS) is one of the most widely used instruments to assess and monitor the severity of symptoms of anxiety and depression. It is sensitive and specific in identifying pathological anxiety, has separate subscales for anxiety and depression, and includes questions that can distinguish symptoms of GAD from anxiety associated with other medical conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Penn State Worry Questionnaire is useful in assessing excessive worrying, has adequate psychometric properties, and is available in a number of languages but may be less sensitive to change than the GAD-7 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H448541462\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of generalized anxiety disorder (GAD) is based on the presence of generalized, persistent and excessive anxiety and a combination of various psychological and somatic complaints.",
"   </p>",
"   <p>",
"    DSM-IV-TR diagnostic criteria for&nbsp;generalized anxiety disorder require [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32776/abstract/54\">",
"     54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Excessive anxiety and worry, occurring more days than not for at least six months, about a number of events or activities",
"     </li>",
"     <li>",
"      The person finds it difficult to control the worry.",
"     </li>",
"     <li>",
"      The anxiety and worry are associated with at least three of the following symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Restlessness",
"     </li>",
"     <li>",
"      Being easily fatigued",
"     </li>",
"     <li>",
"      Difficulty concentrating",
"     </li>",
"     <li>",
"      Irritability",
"     </li>",
"     <li>",
"      Muscle tension",
"     </li>",
"     <li>",
"      Sleep disturbance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The focus of the anxiety and worry is not confined to features of another Axis I disorder, eg, the anxiety or worry is not about having a panic attack, as in panic disorder",
"     </li>",
"     <li>",
"      The anxiety, worry, or physical symptoms cause clinically significant distress or impaired functioning.",
"     </li>",
"     <li>",
"      The disturbance is not due to the direct physiological effects of a substance or a general medical condition",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because the majority of the anxiety symptoms are not specific to GAD, it is important to exclude the other anxiety disorders before making the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/44/44744?source=see_link\">",
"     \"Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44713?source=see_link\">",
"     \"Panic disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27352?source=see_link\">",
"     \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36564?source=see_link\">",
"     \"Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/24/22921?source=see_link\">",
"     \"Specific phobia in adults: Epidemiology, clinical manifestations, course and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The essential feature of diagnostic criteria for GAD in the World Health Organization&rsquo;s ICD-10 is &lsquo;free-floating&rsquo; anxiety, with prominent tension, worry, and feelings of apprehension about everyday events and problems. Diagnosis additionally requires the presence of at least four more features from a list of 22 symptoms relating to autonomic arousal, tension, mental state,",
"    <span class=\"nowrap\">",
"     chest/abdominal",
"    </span>",
"    discomfort, and sleep disturbance. Symptoms have to be present for most days over the preceding six months.",
"   </p>",
"   <p>",
"    The diagnosis of GAD in children and adolescents is described separately. &nbsp;",
"   </p>",
"   <p>",
"    The diagnosis of GAD in elderly individuals can be challenging due to the common co-occurrence of long-term physical illnesses, chronic insomnia, cognitive impairment, and the side effects of prescribed medication. Elderly patients with GAD may assert that anxiety or fear is a realistic response to their social environment, recent life events and current challenges; questions that may be helpful in their assessment include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &ldquo;How do you feel in times of stress?&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;How good are you in controlling any worries?&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H448541476\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H601612644\">",
"    <span class=\"h3\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary GAD with secondary depressive symptoms can be difficult to distinguish from major depression or dysthymia, as the conditions share many features such as an insidious onset, protracted course, prominent dysphoria and anxiety symptoms. Individuals with depression tend to brood self-critically on previous events and circumstances, whereas patients with GAD tend to worry about possible future events. Symptoms of depression such as early morning awakening, diurnal variation in mood, and suicidal thoughts are all uncommon in GAD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H601612651\">",
"    <span class=\"h3\">",
"     Hypochondriasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concern about medically unexplained symptoms is common to both GAD and hypochondriasis, but GAD is usually characterized by worries about multiple different things, while patients with hypochondriasis worry principally about illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H601612658\">",
"    <span class=\"h3\">",
"     Panic disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Panic attacks can occur in GAD, arising out of escalating and uncontrollable worry: but the presence of unexpected (uncued) panic attacks is unusual in GAD. Patients with panic disorder tend to have episodic and calamitous thoughts about presumed life-threatening acute illnesses, whereas patients with GAD focus more persistently on less specific but more chronic complaints involving multiple organ systems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H521922507\">",
"    <span class=\"h3\">",
"     Adjustment disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anxiety and other symptoms occur within three months of an identifiable stressor or stressors. Adjustment disorder is regarded as a &lsquo;residual&rsquo; category in which symptoms do not meet the criteria for another specific disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H448541483\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Generalized anxiety disorder (GAD) is characterized by excessive, persistent worrying which is hard to control, and by psychological and physical symptoms of anxiety that together cause significant personal distress and impairment of everyday functioning. (See",
"      <a class=\"local\" href=\"#H448541396\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      GAD is common in community and clinical settings. It is probably the most common anxiety disorder in people aged over 65 years. Major depression and other anxiety disorders are common comorbidities of GAD. (See",
"      <a class=\"local\" href=\"#H448541403\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Genetic factors appear to predispose individuals to the development of GAD, though data from twin studies have been inconsistent. GAD shares a common heritability with major depression and with the personality trait of &lsquo;neuroticism&rsquo;. Adversity and undesirable life events can exacerbate symptoms of GAD. Neuroimaging and other studies suggest the symptoms of GAD are accompanied by an enhanced emotional responsiveness in fear-related brain circuits. (See",
"      <a class=\"local\" href=\"#H448541410\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Excessive and persistent worrying is the pathognomic symptom of GAD, but symptoms related to hyperarousal, autonomic hyperactivity, motor tension, sleep disturbance and pain are all common. (See",
"      <a class=\"local\" href=\"#H448541448\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      GAD tends to run either a chronic course fluctuating in severity over time, or an episodic course with some intervening periods of relative well-being. Comorbid GAD and major depression is more impairing and has a worse prognosis. (See",
"      <a class=\"local\" href=\"#H448541455\">",
"       'Course'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment of a patient with possible GAD should include a careful history, an evaluation for symptoms of GAD as well as alternative or comorbid psychiatric disorders, and a physical exam and laboratory studies to rule out organic causes of anxiety. (See",
"      <a class=\"local\" href=\"#H601612474\">",
"       'Assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Distinguishing GAD from major depression and dysthymia is probably the most difficult part of the disorder&rsquo;s differential diagnosis, as the conditions share features such as an insidious onset, protracted course, prominent dysphoria and anxiety symptoms. Individuals with depression tend to brood self-critically on previous events and circumstances, whereas patients with GAD tend to worry about possible future events. (See",
"      <a class=\"local\" href=\"#H448541476\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/1\">",
"      Wittchen HU, Zhao S, Kessler RC, Eaton WW. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/2\">",
"      Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/3\">",
"      Kessler RC, Gruber M, Hettema JM, et al. Co-morbid major depression and generalized anxiety disorders in the National Comorbidity Survey follow-up. Psychol Med 2008; 38:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/4\">",
"      Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/5\">",
"      Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe--a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 2005; 15:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/6\">",
"      Wittchen HU, Kessler RC, Beesdo K, et al. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 2002; 63 Suppl 8:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/7\">",
"      Munk-J&oslash;rgensen P, Allgulander C, Dahl AA, et al. Prevalence of generalized anxiety disorder in general practice in Denmark, Finland, Norway, and Sweden. Psychiatr Serv 2006; 57:1738.",
"     </a>",
"    </li>",
"    <li>",
"     Lenze EJ. Anxiety disorders in the elderly. In: Textbook of Anxiety Disorders, 2nd ed, Stein DJ, Hollander E, Rothbaum BO.  (Eds), American Psychiatric Publishing, Inc, Washington, DC 2010. p.651.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/9\">",
"      Brawman-Mintzer O, Lydiard RB, Emmanuel N, et al. Psychiatric comorbidity in patients with generalized anxiety disorder. Am J Psychiatry 1993; 150:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/10\">",
"      Tyrer P, Seivewright H, Johnson T. The Nottingham Study of Neurotic Disorder: predictors of 12-year outcome of dysthymic, panic and generalized anxiety disorder. Psychol Med 2004; 34:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/11\">",
"      Beesdo K, Hoyer J, Jacobi F, et al. Association between generalized anxiety levels and pain in a community sample: evidence for diagnostic specificity. J Anxiety Disord 2009; 23:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/12\">",
"      Allgulander C. Morbid anxiety as a risk factor in patients with somatic diseases: A review of recent findings. Mind Brain 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/13\">",
"      Kendler KS. Major depression and generalised anxiety disorder. Same genes, (partly)different environments--revisited. Br J Psychiatry Suppl 1996; :68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/14\">",
"      Hettema JM, Prescott CA, Kendler KS. Genetic and environmental sources of covariation between generalized anxiety disorder and neuroticism. Am J Psychiatry 2004; 161:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/15\">",
"      Mackintosh MA, Gatz M, Wetherell JL, Pedersen NL. A twin study of lifetime Generalized Anxiety Disorder (GAD) in older adults: genetic and environmental influences shared by neuroticism and GAD. Twin Res Hum Genet 2006; 9:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/16\">",
"      You JS, Hu SY, Chen B, Zhang HG. Serotonin transporter and tryptophan hydroxylase gene polymorphisms in Chinese patients with generalized anxiety disorder. Psychiatr Genet 2005; 15:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/17\">",
"      Donner J, Sipil&auml; T, Ripatti S, et al. Support for involvement of glutamate decarboxylase 1 and neuropeptide Y in anxiety susceptibility. Am J Med Genet B Neuropsychiatr Genet 2012; 159B:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/18\">",
"      Unschuld PG, Ising M, Specht M, et al. Polymorphisms in the GAD2 gene-region are associated with susceptibility for unipolar depression and with a risk factor for anxiety disorders. Am J Med Genet B Neuropsychiatr Genet 2009; 150B:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/19\">",
"      Sevy S, Papadimitriou GN, Surmont DW, et al. Noradrenergic function in generalized anxiety disorder, major depressive disorder, and healthy subjects. Biol Psychiatry 1989; 25:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/20\">",
"      Garvey MJ, Noyes R Jr, Woodman C, Laukes C. The association of urinary 5-hydroxyindoleacetic acid and vanillylmandelic acid in patients with generalized anxiety. Neuropsychobiology 1995; 31:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/21\">",
"      Abelson JL, Glitz D, Cameron OG, et al. Blunted growth hormone response to clonidine in patients with generalized anxiety disorder. Arch Gen Psychiatry 1991; 48:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/22\">",
"      Weizman R, Tanne Z, Granek M, et al. Peripheral benzodiazepine binding sites on platelet membranes are increased during diazepam treatment of anxious patients. Eur J Pharmacol 1987; 138:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/23\">",
"      Ferrarese C, Appollonio I, Frigo M, et al. Decreased density of benzodiazepine receptors in lymphocytes of anxious patients: reversal after chronic diazepam treatment. Acta Psychiatr Scand 1990; 82:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/24\">",
"      Wu JC, Buchsbaum MS, Hershey TG, et al. PET in generalized anxiety disorder. Biol Psychiatry 1991; 29:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/25\">",
"      Nitschke JB, Sarinopoulos I, Oathes DJ, et al. Anticipatory activation in the amygdala and anterior cingulate in generalized anxiety disorder and prediction of treatment response. Am J Psychiatry 2009; 166:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/26\">",
"      Coles ME, Turk CL, Heimberg RG. Memory bias for threat in generalized anxiety disorder: the potential importance of stimulus relevance. Cogn Behav Ther 2007; 36:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/27\">",
"      MacLeod C, Mathews A, Tata P. Attentional bias in emotional disorders. J Abnorm Psychol 1986; 95:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/28\">",
"      Mathews A, Richards A, Eysenck M. Interpretation of homophones related to threat in anxiety states. J Abnorm Psychol 1989; 98:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/29\">",
"      Mogg K, Bradley BP, Millar N, White J. A follow-up study of cognitive bias in generalized anxiety disorder. Behav Res Ther 1995; 33:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/30\">",
"      Mogg K, Baldwin DS, Brodrick P, Bradley BP. Effect of short-term SSRI treatment on cognitive bias in generalised anxiety disorder. Psychopharmacology (Berl) 2004; 176:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/31\">",
"      Safren SA, Gershuny BS, Marzol P, et al. History of childhood abuse in panic disorder, social phobia, and generalized anxiety disorder. J Nerv Ment Dis 2002; 190:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/32\">",
"      Rosenbaum JF, Biederman J, Bolduc-Murphy EA, et al. Behavioral inhibition in childhood: a risk factor for anxiety disorders. Harv Rev Psychiatry 1993; 1:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/33\">",
"      Tyrer P, Seivewright H, Johnson T. The core elements of neurosis: mixed anxiety-depression (cothymia) and personality disorder. J Pers Disord 2003; 17:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/34\">",
"      Khan AA, Jacobson KC, Gardner CO, et al. Personality and comorbidity of common psychiatric disorders. Br J Psychiatry 2005; 186:190.",
"     </a>",
"    </li>",
"    <li>",
"     Beck AT, Emery G, Greenberg RL. Anxiety Disorders and Phobias: A Cognitive Perspective, Basic Books, New York 1985.",
"    </li>",
"    <li>",
"     Barlow DH. Anxiety and Its Disorders: The Nature and Treatment of Anxiety and Panic, Guilford Press, New York 1988.",
"    </li>",
"    <li>",
"     Borkovec TD, Alcaine O, Behar E. Avoidance theory of worry and generalized anxiety disorder. In: Generalized Anxiety Disorder: Advances in Research and Parctice, Heimberg RG, Turk CL, Mennin DS.  (Eds), Guilford Press, New York 2004. p.77.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/38\">",
"      Dugas MJ, Marchand A, Ladouceur R. Further validation of a cognitive-behavioral model of generalized anxiety disorder: diagnostic and symptom specificity. J Anxiety Disord 2005; 19:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/39\">",
"      Wells A, King P. Metacognitive therapy for generalized anxiety disorder: an open trial. J Behav Ther Exp Psychiatry 2006; 37:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/40\">",
"      Roemer L, Molina S, Borkovec TD. An investigation of worry content among generally anxious individuals. J Nerv Ment Dis 1997; 185:314.",
"     </a>",
"    </li>",
"    <li>",
"     Brown TA, O&rsquo;Leary TA, Barlow DH. Generalized anxiety disorder. In: Clinical Handbook of Psychological Disorders, 2nd ed, Barlow DH.  (Ed), Guilford Press, New York 1993. p.137.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/42\">",
"      Bruce SE, Yonkers KA, Otto MW, et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry 2005; 162:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/43\">",
"      Ramsawh HJ, Raffa SD, Edelen MO, et al. Anxiety in middle adulthood: effects of age and time on the 14-year course of panic disorder, social phobia and generalized anxiety disorder. Psychol Med 2009; 39:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/44\">",
"      Angst J, Gamma A, Baldwin DS, et al. The generalized anxiety spectrum: prevalence, onset, course and outcome. Eur Arch Psychiatry Clin Neurosci 2009; 259:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/45\">",
"      Beesdo K, Knappe S, Pine DS. Anxiety and anxiety disorders in children and adolescents: developmental issues and implications for DSM-V. Psychiatr Clin North Am 2009; 32:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/46\">",
"      Shores MM, Glubin T, Cowley DS, et al. The relationship between anxiety and depression: a clinical comparison of generalized anxiety disorder, dysthymic disorder, panic disorder, and major depressive disorder. Compr Psychiatry 1992; 33:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/47\">",
"      Kessler RC, DuPont RL, Berglund P, Wittchen HU. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 1999; 156:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/48\">",
"      Wittchen HU, Carter RM, Pfister H, et al. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol 2000; 15:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/49\">",
"      Tully PJ, Cosh SM, Baune BT. A review of the affects of worry and generalized anxiety disorder upon cardiovascular health and coronary heart disease. Psychol Health Med 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/50\">",
"      Spitzer RL, Kroenke K, Williams JB, L&ouml;we B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/51\">",
"      Kertz S, Bigda-Peyton J, Bjorgvinsson T. Validity of the Generalized Anxiety Disorder-7 Scale in an Acute Psychiatric Sample. Clin Psychol Psychother 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/52\">",
"      Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002; 52:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32776/abstract/53\">",
"      Dear BF, Titov N, Sunderland M, et al. Psychometric comparison of the generalized anxiety disorder scale-7 and the Penn State Worry Questionnaire for measuring response during treatment of generalised anxiety disorder. Cogn Behav Ther 2011; 40:216.",
"     </a>",
"    </li>",
"    <li>",
"     Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text Revision (DSM-IV-TR), American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 496 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-04C97D187A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_0_32776=[""].join("\n");
var outline_f32_0_32776=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H448541483\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H448541396\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H448541403\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H343899757\">",
"      Comorbidity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H448541410\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H448541418\">",
"      Biological factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H448541426\">",
"      Neuropsychological factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H448541433\">",
"      Developmental and personality factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H448541441\">",
"      Cognitive origins of excessive worrying",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H448541448\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H448541455\">",
"      COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H601612474\">",
"      ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H601612593\">",
"      Screening instrument",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H601612600\">",
"      Symptom severity assessment instrument",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H448541462\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H448541476\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H601612644\">",
"      - Depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H601612651\">",
"      - Hypochondriasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H601612658\">",
"      - Panic disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H521922507\">",
"      - Adjustment disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H448541483\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/496\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/496|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/30/32236\" title=\"table 1\">",
"      GAD-7 anxiety scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/22/2409?source=related_link\">",
"      Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36564?source=related_link\">",
"      Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44713?source=related_link\">",
"      Panic disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/38/2665?source=related_link\">",
"      Pharmacotherapy for generalized anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27352?source=related_link\">",
"      Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/1/20505?source=related_link\">",
"      Psychotherapy for generalized anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/44/44744?source=related_link\">",
"      Social anxiety disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/24/22921?source=related_link\">",
"      Specific phobia in adults: Epidemiology, clinical manifestations, course and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/38/37481?source=related_link\">",
"      Unipolar depression in adults: Epidemiology, pathogenesis, and neurobiology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_0_32777="Counseling women considering combined hormonal contraception";
var content_f32_0_32777=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Counseling women considering combined hormonal contraception",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/0/32777/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/0/32777/contributors\">",
"     Vanessa Cullins, MD, MPH, MBA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/0/32777/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/0/32777/contributors\">",
"     Mimi Zieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/0/32777/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/0/32777/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/0/32777/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraception plays an enormous role in enabling women to plan their families. Modern contraceptives are highly effective at preventing pregnancy when used consistently and correctly, and they can be used safely by the vast majority of reproductive age women. Hormonal contraception methods are the most commonly used reversible methods in the United States; almost one-third of female contraceptors use oral contraceptive pills and many of the remainder use a hormonal injection, implant, transdermal patch, vaginal ring, or intrauterine system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/1\">",
"     1",
"    </a>",
"    ]. Although some special considerations are warranted when prescribing hormonal contraception for women with chronic medical disorders, most such women can safely use many of the current array of hormonal contraceptive methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Nevertheless, many women and some clinicians have misperceptions about the health risks of contraceptive hormones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many unplanned pregnancies occur in women who are not using contraception because of barriers to ready access, concerns about adverse events, or dissatisfaction with a method&rsquo;s side effects, lack of convenience, or other bothersome characteristics. Therefore, it is important for health care providers to appropriately counsel women about contraception, with attention to: the woman&rsquo;s values, preferences, and expectations; both contraceptive and noncontraceptive benefits of the method; strategies for dealing with side effects; and strategies for a hassle-free switch to another method when desired by the woman.",
"   </p>",
"   <p>",
"    Dialogue about contraception is conversation between two experts: the health care provider and the woman. The health care provider is the medical, technical expert who can provide basic information about contraceptive methods; the woman is the expert about her needs, her life circumstances, her previous contraceptive experiences, and her expectations for a contraceptive method [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Women report that they want to be treated as equal partners during this dialogue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BASIC INFORMATION ABOUT CONTRACEPTIVE CHOICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to making decisions about contraceptive methods that might work well for them, women usually want to understand the method's [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Efficacy",
"     </li>",
"     <li>",
"      Duration of action",
"     </li>",
"     <li>",
"      Mechanism of action",
"     </li>",
"     <li>",
"      Ease of reversibility and time to return of fertility",
"     </li>",
"     <li>",
"      Privacy of use",
"     </li>",
"     <li>",
"      Convenience",
"     </li>",
"     <li>",
"      Risks and side effects, particularly the bleeding profile",
"     </li>",
"     <li>",
"      Ease of repeated access",
"     </li>",
"     <li>",
"      Cost per month and over the duration of time contraception will be needed",
"     </li>",
"     <li>",
"      Additional health benefits",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, successful counseling also takes into account that clients differ and their situations differ, so they need different kinds and differing quantities of information [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34055285\">",
"    <span class=\"h1\">",
"     ASSESSING VALUES, PREFERENCES, AND GOALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to clarify the woman's needs, concerns, and expectations about a contraceptive method to help her make an informed decision about which method is best for her at her current point in life. Her needs, concerns, and expectations are influenced by several factors, including some or all of those listed below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Personal preferences",
"     </li>",
"     <li>",
"      Childbearing plans (number of children, timing of next pregnancy) and attitudes about an unintended pregnancy",
"     </li>",
"     <li>",
"      Pattern of sexual activity (frequency of sex, number of partners)",
"     </li>",
"     <li>",
"      Partner influences and concerns",
"     </li>",
"     <li>",
"      Social and cultural factors (eg, religious beliefs)",
"     </li>",
"     <li>",
"      Ability to use the method successfully",
"     </li>",
"     <li>",
"      Prior method-specific experiences",
"     </li>",
"     <li>",
"      Cost",
"     </li>",
"     <li>",
"      Ease of repeat administration",
"     </li>",
"     <li>",
"      Supportive care from the health care provider",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The answers to the following questions can help the provider and woman think about factors that should influence her contraceptive choice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Do you have any plans of becoming pregnant any time in the future? If so, when?\"",
"     </li>",
"     <li>",
"      \"How important is it to avoid pregnancy right now? What would you do if you became pregnant before you intended? Would abortion be an option?\"",
"     </li>",
"     <li>",
"      &ldquo;Is it important to you to use a nonprescription method or a method that doesn&rsquo;t require a visit to a provider at least once per year?&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Are you willing to use a method of contraception that contains or releases hormones?&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Do you have a latex allergy or sensitivity?&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;What is most important to you about your method of contraception: cost, efficacy, how often you need to take it, when you need to take it, type and frequency of side effects, privacy?&rdquo;",
"     </li>",
"     <li>",
"      \"Do you want (or need) use of contraception to be private? Do you need a method that your partner or others can't detect?\"",
"     </li>",
"     <li>",
"      \"What side effects are you willing to accept or live with? In particular, would not having a period make you anxious or would you see it as a benefit? Can you accept an increased risk of unscheduled",
"      <span class=\"nowrap\">",
"       bleeding/spotting",
"      </span>",
"      as a trade-off for the convenience of a non-daily hormonal method or instead of monthly periods? Can you accept having heavier periods as a side effect?&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Do you have a strong preference for contraception that is used only when you have sex, daily, weekly, monthly, or less often than monthly?&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Are you in a mutually monogamous relationship?&rdquo; If not, protection from sexually transmitted infections should be a factor in choosing the contraceptive method or methods.",
"     </li>",
"     <li>",
"      &ldquo;Are you likely to remember to take a pill daily?&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Are you and your partner willing to interrupt sex to put birth control in place?&rdquo;",
"     </li>",
"     <li>",
"      \"Are you comfortable with methods that require insertion in the vagina?\"",
"     </li>",
"     <li>",
"      &ldquo;Are you willing to have an injection every three months for a year or more?&rdquo;",
"     </li>",
"     <li>",
"      \"Do you have concerns about a particular contraceptive?\" (An affirmative answer should be followed with the question, \"What method are you concerned about and what are your concerns?\")",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MEDICAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical assessment to identify women who are not candidates for hormonal contraception is primarily based upon standard medical history and measurement of blood pressure (ie, exclusion of poorly controlled hypertension) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/2-5,8\">",
"     2-5,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Again, once a woman is deemed a candidate for hormonal contraception, her values and preferences should dictate which method she uses and for how long.",
"   </p>",
"   <p>",
"    Estrogen-progestin contraceptive pills, the vaginal ring, and the contraceptive patch should be considered as one class of combined hormonal contraception with similar efficacy when used consistently and correctly. The safety and side effect profiles are also similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/2-5,13\">",
"     2-5,13",
"    </a>",
"    ]. This is important when conveying information about risks and benefits of these contraceptives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/14-17\">",
"     14-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34055928\">",
"    <span class=\"h2\">",
"     Pre-existing medical conditions and personal characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical conditions that may develop or worsen because of increased exposure to estrogen or progesterone are contraindications to use of hormonal contraceptives. These medical conditions also confer risk to the woman if she becomes pregnant, given that estrogen and progesterone levels increase even more during pregnancy than with administration of hormonal contraception.",
"   </p>",
"   <p>",
"    Relatively few reproductive age women are ineligible for hormonal contraception. In the only study of a large, nationally representative sample of women in the United States, oral contraceptives were contraindicated in just 16 percent of women aged 20 to 51 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The World Health Organization (WHO) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/2\">",
"     2",
"    </a>",
"    ] and the US Centers for Disease Control and Prevention (CDC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/3-5\">",
"     3-5",
"    </a>",
"    ] have published similar comprehensive tables of medical conditions and personal characteristics that may affect contraceptive choice. The CDC recommendations are listed in the following table (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"     table 1",
"    </a>",
"    ); WHO recommendations can be found online and in the topic review on overview of contraception. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39306?source=see_link\">",
"     \"Overview of contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some additional points:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Combined estrogen-progestin contraceptives should be avoided in women with inherited thrombophilias; however, most experts do not recommend routine screening for these conditions prior to prescribing hormonal contraception due to the low yield and high cost [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/19\">",
"       19",
"      </a>",
"      ]. Additional considerations when prescribing hormonal contraceptives for obese women and women with inherited thrombophilias are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/8/4233?source=see_link\">",
"       \"Contraception counseling for obese women\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26759?source=see_link\">",
"       \"Contraception for women with inherited thrombophilias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Orally administered gonadal steroids are metabolized in the liver so metabolism is altered in women with active liver disease. Examples of active liver disease include tumors, active viral hepatitis, and severe cirrhosis. The risk of mild liver disease may be slightly increased in women who take an OC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/2-5,20\">",
"       2-5,20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/63/29690?source=see_link\">",
"       \"Drugs and the liver: Patterns of drug-induced liver injury\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link&amp;anchor=H34#H34\">",
"       \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Liver disorders'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Blood pressure needs to be monitored in women with controlled hypertension because of risk of exacerbation of hypertension. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link&amp;anchor=H9#H9\">",
"       \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Hypertension'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37859?source=see_link\">",
"       \"Effect of oral contraceptives and postmenopausal hormone therapy on blood pressure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Contraceptive efficacy may be reduced in women taking some types of anticonvulsants because of accelerated catabolism of the orally administered gonadal steroids. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=see_link&amp;anchor=H20#H20\">",
"       \"Overview of the management of epilepsy in adults\", section on 'Oral contraceptive therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women taking medications that increase serum potassium or that potentially alter renal function need monitoring of potassium level, if prescribed drospirenone containing combined hormonal contraceptives (Yaz&reg;, Yasmin&reg;). Examples of such drugs include angiotensin converting enzyme (ACE) inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , aldosterone antagonists, potassium supplements, and long-term daily use of nonsteroidal anti-inflammatory drugs. These women should have their serum potassium level checked during the first treatment cycle. In addition, drospirenone containing combined hormonal contraceptives should not be used in women with conditions that predispose to hyperkalemia, such as renal insufficiency, hepatic dysfunction, or adrenal insufficiency. Any of the other combined hormonal contraceptive methods containing non-drospirenone progestins may be prescribed.",
"     </li>",
"     <li>",
"      Vomiting, diarrhea, and drug interactions can transiently decrease the effectiveness of OCs. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link\">",
"       \"Overview of the use of estrogen-progestin contraceptives\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The decision to continue or stop an estrogen-progestin contraceptive before surgery must balance the risk of unwanted pregnancy against the risk of thromboembolism. It is reasonable to continue an estrogen-progestin contraceptive in patients who are undergoing low risk surgery. Definitions of low, moderate, and high risk procedures are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link&amp;anchor=H5#H5\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Surgical risk groups'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In general, an estrogen-progestin contraceptive should be discontinued four to six weeks prior to moderate or high risk surgery. The estrogen-progestin contraceptive can be re-started postoperatively when the woman is fully ambulatory. In rare situations, an estrogen-progestin contraceptive might be continued in moderate to high risk women who could have difficulty complying with other forms of contraception, recognizing that this may increase their risk of thromboembolism; thromboembolic prophylaxis should be planned accordingly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35391008\">",
"    <span class=\"h1\">",
"     COUNSELING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Information to guide counseling about the magnitude of thrombotic risk",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Risk of VTE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common estimate of risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) among women ages 15 to 44 years who are not pregnant and not using combined hormonal contraception is 5 to 10 cases per 100,000 woman years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. The risk of venous thromboembolism (VTE) increases with administration of exogenous estrogen preparations. For combined oral contraceptives, the increase in risk is two- to four-fold, depending upon whether the progestin is second generation (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    ), third generation (eg, desogestrel or gestodene not available in the United States), or fourth generation (eg, drospirenone) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In general, the lowest VTE risk is seen with estrogen-progestin contraceptives that use the progestin levonorgestrel.",
"   </p>",
"   <p>",
"    However, when assessing the magnitude of any risk, it is important initially to focus upon absolute risks rather than relative risks. If an event is rare, a comparison of options may become distorted if the focus is only upon relative risks. Absolute risk is the proportion of people within a group who experience the event; it is the number of people with the event divided by the number of people at risk for the event.",
"   </p>",
"   <p>",
"    Thus, while the magnitude of increase initially may appear alarming, this increase translates into an absolute risk of deep vein thrombosis and pulmonary embolism among low-dose estrogen-progestin contraceptive users of 20 to 30 per 100,000 women-years",
"    <span class=\"nowrap\">",
"     (20/100,000",
"    </span>",
"    for second generation oral contraceptives and",
"    <span class=\"nowrap\">",
"     30/100,000",
"    </span>",
"    for low dose estrogen-progestin contraceptives containing desogestrel, gestodene, or drospirenone) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/21\">",
"     21",
"    </a>",
"    ]. These absolute risks are quite small compared to the risk of venous thromboembolism associated with a pregnancy that goes to term (60 to 96 per 100,000 women-years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/24,27\">",
"     24,27",
"    </a>",
"    ], or being postpartum (511 per 100,000 woman years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/24,27,28\">",
"     24,27,28",
"    </a>",
"    ]. Based on these figures, combined hormonal contraception clearly is a safe alternative to unwanted pregnancy.",
"   </p>",
"   <p>",
"    If the baseline rate of VTE is actually higher and absolute risks from observational studies of VTE among oral contraceptive users remain constant, then the",
"    <strong>",
"     increase",
"    </strong>",
"    in risk of VTE from using combined hormonal contraception is even smaller than currently reported. This is important because a recent analysis of published studies reported several cohort studies with baseline incidences of VTE ranging from 6 to 160 per 100,000 woman-years (majority of studies ranging from 14 to 33 per 100,000 woman-years) in women of reproductive age not exposed to hormones, which is higher than previous estimates of 5 to 10 per 100,000 woman-years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/28\">",
"     28",
"    </a>",
"    ]. In other words, if baseline risk of VTE is higher than previously reported, the increase in risk from exposure to hormonal contraceptive use is more minimal than previously reported. Therefore, providers and healthy reproductive age women can be less anxious about low dose combined hormonal contraception and risk of VTE.",
"   </p>",
"   <p>",
"    In summary, there have been concerns that newer progestins (desogestrel and gestodene) and antiandrogens (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14374?source=see_link\">",
"     cyproterone acetate",
"    </a>",
"    , drospirenone) are associated with a greater risk of VTE compared to earlier progestational agents. The absolute excess risk is extremely small, and is considered medically acceptable given the many benefits of combined hormonal contraceptives. The risk of VTE with newer progestins and antiandrogens is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=see_link&amp;anchor=H13#H13\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Type of progestin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Risk of arterial events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial events (ischemic or hemorrhagic strokes and myocardial infarctions) are rare among users of any of the current forms of combined hormonal contraception (vaginal ring, contraceptive patch, and low-dose oral contraceptives). This is in contrast to oral contraceptive preparations marketed in the 1960s and early 1970s, which contained three to five times the estrogen doses found in modern oral contraceptives.",
"   </p>",
"   <p>",
"    A 15-year Danish historical cohort study evaluated data from national registries to determine the risk of arterial events, thrombotic stroke and myocardial infarction, in users of hormonal contraception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/29\">",
"     29",
"    </a>",
"    ]. The cohort included the entire population of Danish women, 15 to 49 years of age, for the period 1995 through 2009. A total of 1,626,158 women contributed 14,251,063 person-years of observation; users of hormonal contraception experienced a total of 4.9 million person-years of use. In the entire cohort of users and nonusers, there were 3311 thrombotic strokes and 1725 myocardial infarctions (MI). Risks increased dramatically with age, such that stroke was 20 times and MI was 100 times more likely in those aged 45 to 49 years compared with the youngest cohort of 15 to 19 years (includes users and nonusers of hormonal contraception). The crude incidence rates for hormonal users (who tend to be younger and healthier) were 21.4 per 100,000 person-years for thrombotic strokes and 10.1 per 100,000 for MIs compared with rates of 24.2 and 13.2 per 100,000, respectively, for nonusers; these rates are higher presumably due to older age and more risk factors among nonusers.",
"   </p>",
"   <p>",
"    However, when adjusted for age, educational level, calendar year, and risk factors (diabetes, hypertension, hyperlipidemia, arrhythmia, smoking), the risks of thrombotic stroke and MI according to estrogen dose and progestin type in current users of oral contraceptives were slightly higher than in nonusers:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ethinyl estradiol 30 to 40 mcg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/52/16199?source=see_link\">",
"       norethindrone",
"      </a>",
"      RR stroke 2.2 (95% CI 1.5-3.2) and RR MI 2.3 (95% CI 1.3-3.9)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"       levonorgestrel",
"      </a>",
"      RR stroke 1.7 (95% CI 1.4-2.0) and RR MI 2.0 (95% 1.6-2.5)",
"     </li>",
"     <li>",
"      norgestimate RR stroke 1.5 (95% CI 1.2-1.9) and RR MI 1.3 (95% CI 0.9-1.9)",
"     </li>",
"     <li>",
"      desogestrel RR stroke 2.2 (95% CI 1.8-2.7) and RR MI 2.1 (95% CI 1.5-2.8)",
"     </li>",
"     <li>",
"      gestodene RR stroke 1.8 (95% CI 1.6-2.0) and RR MI 1.9 (95% CI 1.6-2.3)",
"     </li>",
"     <li>",
"      drospirenone RR stroke 1.6 (1.2-2.2) and RR MI 1.7 (95% CI 1.0-2.6)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ethinyl estradiol 20 mcg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      desogestrel RR stroke 1.5 (95% CI 1.3-1.9) and RR MI 1.6 (95% CI 1.1-2.1)",
"     </li>",
"     <li>",
"      gestodene RR stroke 1.7 (95% CI 1.4-2.1) and RR MI 1.2 (95% CI 0.8 to 1.9)",
"     </li>",
"     <li>",
"      drospirenone RR stroke 0.9 (95% CI 0.2-3.5) and RR MI 0.0",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of thrombotic stroke was also slightly increased in contraceptive patch users: RR 3.15 (95% CI 0.79-12.6) and ring users: RR 2.49 (95% CI 1.41-4.41). For MI, the risks in patch and ring users were RR 0 (95% CI 0.0-63.10) and RR 2.08 (95% CI 0.67-6.48), respectively.",
"   </p>",
"   <p>",
"    As can be seen from relative risks cited above, the greatest gradient of risk is associated with increasing estrogen dose, rather than progestin type. Moreover, although the relative risks of arterial events in users were slightly increased, the absolute risks remained very small, and probably acceptable to most women, given the contraceptive and noncontraceptive benefits of hormonal contraception. Important risk factors to consider were age, hypertension, hyperlipidemia and diabetes. As with venous thromboembolic events, the absolute risks of arterial thrombotic events are higher during pregnancy and postpartum than with use of combined hormonal contraception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/16,17,23,24,27,30\">",
"     16,17,23,24,27,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Effect of smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking poses a significant risk for myocardial infarction and is a contraindication for estrogen containing contraception among women ages 35 years and older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Smokers who do not use oral contraception have the following absolute risks for myocardial infarction: 1.083 per one million woman-years for women ages 20 to 24; 13.58 for women ages 30 to 34; and 170 per one million woman-years for women ages 40 to 44 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/31\">",
"     31",
"    </a>",
"    ]. Corresponding risks for smokers who use combined hormonal contraception are: 1.6 per one million women-years for ages 20 to 24; 20 per million woman-years for those ages 30 to 34 and 255.3 per one million woman-years for women ages 40 to 44 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Information on counseling about side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects are very common reasons for contraceptive discontinuation. Studies show that as many as 65 percent of women discontinue oral contraceptive pills because of side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/15,32,33\">",
"     15,32,33",
"    </a>",
"    ]. The side effects may frighten the user, either because the side effects are unexpected or because the user feels it is unhealthy to experience the side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/11,15,34,35\">",
"     11,15,34,35",
"    </a>",
"    ], or the side effects may just be too bothersome. The more common side effects leading to discontinuation include unscheduled bleeding, nausea, unexpected weight gain, mood changes, breast tenderness, and headaches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/36\">",
"     36",
"    </a>",
"    ]. In addition, patch users may discontinue their method because of skin site reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/37\">",
"     37",
"    </a>",
"    ] and ring users may discontinue their method due to vaginal discharge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the woman has no contraindications to a hormonal contraception method and is bothered by side effects, she needs to try another method that she thinks she might like in order to find out what her side effect profile will be with the new method. While some providers may prescribe different hormonal formulations to ameliorate bothersome side effects, there is no strong scientific rationale for making choices; it is all trial and error, so women should be allowed to easily switch between methods and formulations, whether combined hormonal, or progestin-only, or non-hormonal methods. When switching, the woman should be instructed to begin the new formulation or method immediately without a gap in contraceptive coverage and she should be warned that temporary breakthrough bleeding may occur if the new formulation results in weaker estrogenic effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4142766\">",
"    <span class=\"h3\">",
"     Unscheduled bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;While providers and women cannot accurately predict the exact side effect profile a woman will experience, some general statements may prove useful to women trying to decide among hormonal contraceptive methods.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When any hormonal method is initiated or when there are changes in formulation or a dose is missed or taken late, women should expect breakthrough bleeding or spotting. Breakthrough bleeding is particularly common in the first few months of use with extended pill regimens, such as the",
"      <span class=\"nowrap\">",
"       84/7",
"      </span>",
"      or 365 day regimens. New start oral contraceptive users who choose a 20 mcg ethinyl estradiol preparation experience more breakthrough bleeding than starters using higher dose formulations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/39\">",
"       39",
"      </a>",
"      ]. Formulations that contain a low dose of estrogen (eg, 10 mcg) during the first few days of the last seven days of the regimen theoretically result in less breakthrough bleeding compared to those formulations that contain no hormone during the regimen&rsquo;s last seven days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      All users of progestin-only methods should expect irregular, unpredictable bleeding during initial weeks to months of method use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Side effects for progestin-only hormonal contraception can include all those for combined hormonal contraceptive methods. However, the frequency of irregular, unpredictable bleeding is far higher with progestin-only methods, and such bleeding is experienced by virtually all users of these methods. In fact, eventual, cyclical bleeding is least likely in users of the contraceptive implant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Eventual hypomenorrhea, oligomenorrhea, or amenorrhea is the most common outcome for users of the 52 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    -releasing intrauterine device (LNg20-IUD) or depot",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (DMPA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/41,44\">",
"     41,44",
"    </a>",
"    ]. Although bleeding may be unexpected and frequent, the volume is small so there is no increased risk of anemia.",
"   </p>",
"   <p>",
"    Issues pertaining to unscheduled bleeding are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/10/22698?source=see_link\">",
"     \"Management of unscheduled bleeding in women using contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4142687\">",
"    <span class=\"h3\">",
"     Change in libido",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies on the effect of contraceptive hormones on libido have reported inconsistent findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/45-51\">",
"     45-51",
"    </a>",
"    ]. In these studies, there was no clear or consistent relationship between the type of progestin, serum androgen levels, and female sexual satisfaction. In clinical practice, some women who experience decreased libido do not bring this up for discussion with their provider. Thus, it can be useful to ask about changes in libido during follow-up visits.",
"   </p>",
"   <p>",
"    If decreased sexual satisfaction is related to vaginal dryness, use of lubricants or a more estrogenic contraceptive preparation may be useful. Although there is no strong evidence to support a change in the contraceptive regimen, women with decreased libido may benefit from a more androgenic preparation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27702900\">",
"    <span class=\"h3\">",
"     Change in weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some women avoid combined estrogen-progestin contraceptives because of concerns about weight gain related to their use, but evidence does not support this association.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review of placebo-controlled randomized trials did not find evidence supporting a causal association between use of combination oral contraceptives or combination skin patch and weight gain over the short term (six months) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A longitudinal study over decades reported no significant difference in weight gain in women grouped according to use or non-use of combined oral contraceptive pills or duration of use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study in rhesus monkeys given an estrogen-progestin oral contraceptive (dosed to achieve equivalent human serum levels for a 30 mcg ethinyl",
"      <span class=\"nowrap\">",
"       estradiol/150",
"      </span>",
"      mcg",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"       levonorgestrel",
"      </a>",
"      preparation) continuously for 237 days found body weight and percent body fat remained stable in the normal body mass index (BMI) group and significantly decreased in the obese BMI group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A systematic review of studies (progestin-only pills n = 1 study, Norplant n = 4 studies, DMPA n = 10 studies) on the effects of progestin-only contraceptives on weight concluded there was little evidence of weight gain with use of these contraceptives [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/55\">",
"       55",
"      </a>",
"      ] among adult women. Mean gain was less than 2 kg for most studies up to 12 months, and generally similar to that of the comparison group using another contraceptive. However, DMPA users, especially adolescents who gain more than 5 percent additional weight after six months of DMPA use, are likely to experience more weight gain than expected, given diet and lifestyle [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/56\">",
"       56",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/45/34522?source=see_link&amp;anchor=H11#H11\">",
"       \"Depot medroxyprogesterone acetate for contraception\", section on 'Weight changes'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Counseling about noncontraceptive benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to their high contraceptive efficacy when used consistently and correctly, women should be aware of the many potential noncontraceptive benefits of estrogen-progestin contraceptives, as listed in the table (",
"    <a class=\"graphic graphic_table graphicRef82147 \" href=\"mobipreview.htm?32/35/33339\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/57-65\">",
"     57-65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Noncontraceptive health benefits in progestin-only users (eg, POPs, DMPA, LNg20 IUD) include reduced iron deficiency anemia among long-term users, improved hematologic parameters among users with sickle cell disease, and protection against endometrial cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/41,66-68\">",
"     41,66-68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     STRATEGIES FOR ENHANCING COMPLIANCE AND CONTINUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;To prevent unplanned pregnancies, contraception must be used correctly and consistently. Almost half (49 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/69\">",
"     69",
"    </a>",
"    ] of all unintended pregnancies occur among contraceptors and 90 percent of these pregnancies are estimated to result from incorrect or inconsistent method use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/11,14,70,71\">",
"     11,14,70,71",
"    </a>",
"    ]. As an example, a study of a nationally representative sample of American women ages 18 to 44 using reversible contraceptive methods noted that 38 percent reported inconsistent use of birth control pills (ie, they missed at least one pill in the previous three months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among users of daily oral contraceptive pills, missing pills is common and a factor in unintended pregnancy. For users of daily contraceptive pills, having the male partner simultaneously use a male condom enhances pregnancy protection if a pill is missed and also provides protection against sexually transmitted diseases. Importantly, if she switches to a non-daily method, such as the contraceptive ring, patch, or implant; DMPA; or intrauterine contraception, adherence can improve considerably [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/72-74\">",
"     72-74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A report by the Guttmacher Institute recommended the following strategies for improving women's contraceptive use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Provide ongoing support for contraceptive use based on regular assessment of the client's sexual activity, relationships, attitudes about pregnancy, and life events (changes in partners, job, school, housing, personal crises).",
"     </li>",
"     <li>",
"      Improve the client's knowledge of different contraceptive methods and their risks and benefits, including noncontraceptive benefits.",
"     </li>",
"     <li>",
"      Anticipate and manage side effects.",
"     </li>",
"     <li>",
"      Address cost and access barriers.",
"     </li>",
"     <li>",
"      Provide clear information about ways to remember to take pills (eg, daily text messages [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/75,76\">",
"       75,76",
"      </a>",
"      ], set alarm on cell phone, computer alert), what to do if one or more pills are missed, back-up contraception, and emergency contraception (including advance provision).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As long as the woman maintains the same contraceptive eligibility status, she should be able to switch between contraceptive methods, as she chooses, without unnecessary provider-imposed, medical barriers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/35\">",
"     35",
"    </a>",
"    ]. Such barriers lead to gaps in contraceptive use and unintended pregnancy. For example, the provider should",
"    <strong>",
"     not",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/6,77-80\">",
"     6,77-80",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Require that women be menstruating prior to beginning hormonal contraception. (Instead use a \"quick start method\") &nbsp;",
"     </li>",
"     <li>",
"      Require a visit to a health care provider prior to switching from one hormonal contraceptive to another. (Instead, phone a prescription to her pharmacy)",
"     </li>",
"     <li>",
"      Require a pelvic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      breast examination prior to beginning hormonal contraceptive. (Only blood pressure measurement is required)",
"     </li>",
"     <li>",
"      Dispense only one packet of oral contraceptives at a time. (Dispensing one year&rsquo;s supply of pill packs enhances compliance, reduces unintended pregnancy, and is cost effective [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/79-82\">",
"       79-82",
"      </a>",
"      ])",
"     </li>",
"     <li>",
"      Attempt to steer a medically eligible woman away from a method that she wants to try.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While observational studies tend to report contraception counseling increases use of contraception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/83-85\">",
"     83-85",
"    </a>",
"    ], there are only limited data from randomized trials. A systematic review found eight randomized trials that attempted to determine the effectiveness of counseling procedures and techniques in improving adherence to, and continuation rates of, hormonal methods of contraception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/0/32777/abstract/86\">",
"     86",
"    </a>",
"    ]. Two trials showed a statistically significant benefit of enhanced counseling compared to routine care. In one trial, women who received repeated, structured information about the injectable contraceptive DMPA were less likely to discontinue the method by 12 months (OR 0.27; 95% CI 0.16-0.44) and less likely to discontinue due to menstrual disturbances (OR 0.20; 95% CI 0.11-0.37). In another trial, the intervention group was less likely to discontinue due to dissatisfaction with the contraceptive method (OR 0.61; 95% CI 0.38-0.98), but overall continuation was not affected. Available trials had important limitations, such as small sample sizes, high losses to follow up, and differences in the type and application of the counseling intervention, populations, and outcomes. No trial has provided definitive guidance about effective counseling techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/17/18707?source=see_link\">",
"       \"Patient information: Hormonal birth control (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/60/9157?source=see_link\">",
"       \"Patient information: Birth control; which method is right for me? (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/32/22021?source=see_link\">",
"       \"Patient information: Hormonal methods of birth control (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once a woman is deemed a candidate for hormonal contraception medically, her values and preferences should dictate which method she uses. (See",
"      <a class=\"local\" href=\"#H34055285\">",
"       'Assessing values, preferences, and goals'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H34055928\">",
"       'Pre-existing medical conditions and personal characteristics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most women, even those with chronic medical disorders, can safely use any of the current array of contraceptive methods. (See",
"      <a class=\"local\" href=\"#H34055928\">",
"       'Pre-existing medical conditions and personal characteristics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Estrogen-progestin contraceptive pills, the vaginal ring, and the contraceptive patch should be considered as one class of combined hormonal contraception with similar efficacy when used consistently and correctly. The safety and side effect profiles are also similar. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Information to guide counseling about the magnitude of thrombotic risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When any hormonal method is initiated or when there are changes in formulation or a dose is missed or taken late, women should expect breakthrough bleeding or spotting. All users of progestin-only methods should expect irregular, unpredictable bleeding. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Information on counseling about side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women should be made aware of the noncontraceptive benefits of hormonal contraceptives, such as reduction in risk of some cancers and improvement in dysmenorrhea. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Counseling about noncontraceptive benefits'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Providers can enhance contraceptive success by",
"      <span class=\"nowrap\">",
"       counseling/informing",
"      </span>",
"      the woman so that she chooses the most appropriate method for herself given her current life circumstances. By motivating her to be compliant, and by removing unnecessary medical barriers to contraceptive access and continuation, the provider may enhance method satisfaction and use. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Strategies for enhancing compliance and continuation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/1\">",
"      Mosher WD, Martinez GM, Chandra A, et al. Use of contraception and use of family planning services in the United States: 1982-2002. Adv Data 2004; :1.",
"     </a>",
"    </li>",
"    <li>",
"     Medical eligibility criteria for contraceptive use www.who.int/reproductivehealth/publications/family_planning/.../en/ (Accessed on July 10, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/3\">",
"      Centers for Disease Control and Prevention (CDC). U S. Medical Eligibility Criteria for Contraceptive Use, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/4\">",
"      Centers for Disease Control and Prevention (CDC). Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: revised recommendations for the use of contraceptive methods during the postpartum period. MMWR Morb Mortal Wkly Rep 2011; 60:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/5\">",
"      Centers for Disease Control and Prevention (CDC). Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: revised recommendations for the use of hormonal contraception among women at high risk for HIV infection or infected with HIV. MMWR Morb Mortal Wkly Rep 2012; 61:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/6\">",
"      Shelton JD, Angle MA, Jacobstein RA. Medical barriers to access to family planning. Lancet 1992; 340:1334.",
"     </a>",
"    </li>",
"    <li>",
"     Trussell J. Choosing a Contraceptive: efficacy, safety, and personal considerations. In: Contraceptive Technology, 19th ed, Hatcher RA, Trussell J, Nelson AL, Cates W, Stewart FH, Kowal D (Eds), Ardent Media, Inc, New York 2007. p.19.",
"    </li>",
"    <li>",
"     World Health Organization Department of Reproductive Health and Research (WHO/RHR) and Johns Hopkins Bloomberg School of Public Health/Center for Communications Programs (CCP), INFO Project. Family Planning: a global handbook for providers, CCP and WHO, Baltimore and Geneva 2007.",
"    </li>",
"    <li>",
"     Reproductive Health Technologies Project and the Alan Guttmacher Institute. The Unfinished Revolution in Contraception: convenience, consumer access and choice. Conference Report. October, 2003. file://www.guttmacher.org/pubs/2004/09/20/UnfinRevInContra.pdf. (Accessed on July 09, 2012).",
"    </li>",
"    <li>",
"     The Pro-Choice Public Education Project. She Speaks: African American and Latino Young Women on Reproductive Health and Rights 2004. p.17. file://www.protectchoice.org/downloads/She%20Speaks%20Report%20Full. (Accessed on July 09, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/11\">",
"      Frost JJ, Darroch JE. Factors associated with contraceptive choice and inconsistent method use, United States, 2004. Perspect Sex Reprod Health 2008; 40:94.",
"     </a>",
"    </li>",
"    <li>",
"     Association of Reproductive Health Professionals: ARHP Clinical Proceedings, 2006. p.13.",
"    </li>",
"    <li>",
"     Hatcher RA, Trussell J, Nelson AL, et al. Contraceptive Technology, 20th ed, Ardent Media, Inc, New York 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/14\">",
"      Moreau C, Cleland K, Trussell J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception 2007; 76:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/15\">",
"      Potter L, Oakley D, de Leon-Wong E, Ca&ntilde;amar R. Measuring compliance among oral contraceptive users. Fam Plann Perspect 1996; 28:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/16\">",
"      Trussell J, Jordan B. Reproductive health risks in perspective. Contraception 2006; 73:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/17\">",
"      Gardner J, Miller L. Promoting the safety and use of hormonal contraceptives. J Womens Health (Larchmt) 2005; 14:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/18\">",
"      Shortridge E, Miller K. Contraindications to oral contraceptive use among women in the United States, 1999-2001. Contraception 2007; 75:355.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization (WHO). Improving access to quality care in family planning. In: Medical Eligibility criteria for contraceptive use. 3rd edition, Geneva, Switzerland, 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/20\">",
"      Hannaford PC, Kay CR, Vessey MP, et al. Combined oral contraceptives and liver disease. Contraception 1997; 55:145.",
"     </a>",
"    </li>",
"    <li>",
"     European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products CPMP Public Assessment Report: Combined oral contraceptives and venous thromboembolism. file://www.emea.europa.eu/pdfs/human/regaffair/0220101en.pdf. (Accessed on July 09, 2012).",
"    </li>",
"    <li>",
"     Prescriber Update Article: Venous thromboembolism with Diane 35&trade; and Estelle 35&trade;. Prescriber Update 2002;23(1):2-3. file://www.medsafe.govt.nz/Profs/PUarticles/VTEwithCPA.htm (Accessed on July 09, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/23\">",
"      Shulman LP, Goldzieher JW. The truth about oral contraceptives and venous thromboembolism. J Reprod Med 2003; 48:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/24\">",
"      Mishell DR, Shulman LP: Venous thromboembolism and cardiovascular disease: hormonal contraception. Dialogues Contracept 2007; 11:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/25\">",
"      van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009; 339:b2921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/26\">",
"      Lidegaard &Oslash;, L&oslash;kkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339:b2890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/27\">",
"      Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/28\">",
"      Heinemann LA, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. Contraception 2007; 75:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/29\">",
"      Lidegaard &Oslash;, L&oslash;kkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012; 366:2257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/30\">",
"      Mills A. Combined oral contraception and the risk of venous thromboembolism. Hum Reprod 1997; 12:2595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/31\">",
"      World Health Organization. Report of a WHO Scientific Group. WHO Technical Series - 877. Cardiovascular disease and steroid hormonal contraception 1998; 877:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/32\">",
"      Rosenberg MJ, Waugh MS, Burnhill MS. Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation. Fam Plann Perspect 1998; 30:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/33\">",
"      Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 1995; 51:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/34\">",
"      Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998; 179:577.",
"     </a>",
"    </li>",
"    <li>",
"     Improving Contraceptive Use in the United States. Guttmacher Institute. 2008. www.guttmacher.org/pubs/2008/05/09/ImprovingContraceptiveUse.pdf. (Accessed on July 09, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/36\">",
"      Westhoff CL, Heartwell S, Edwards S, et al. Oral contraceptive discontinuation: do side effects matter? Am J Obstet Gynecol 2007; 196:412.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/37\">",
"      Bakhru A, Stanwood N. Performance of contraceptive patch compared with oral contraceptive pill in a high-risk population. Obstet Gynecol 2006; 108:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/38\">",
"      Roumen FJ. The contraceptive vaginal ring compared with the combined oral contraceptive pill: a comprehensive review of randomized controlled trials. Contraception 2007; 75:420.",
"     </a>",
"    </li>",
"    <li>",
"     Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF. 20 &micro;g versus &gt;20 &micro;g estrogen combined oral contraceptives for contraception. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD003989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/40\">",
"      Cremer M, Phan-Weston S, Jacobs A. Recent innovations in oral contraception. Semin Reprod Med 2010; 28:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/41\">",
"      Blumenthal PD, Edelman A. Hormonal contraception. Obstet Gynecol 2008; 112:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/42\">",
"      Mansour D, Korver T, Marintcheva-Petrova M, Fraser IS. The effects of Implanon on menstrual bleeding patterns. Eur J Contracept Reprod Health Care 2008; 13 Suppl 1:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/43\">",
"      Blumenthal PD, Gemzell-Danielsson K, Marintcheva-Petrova M. Tolerability and clinical safety of Implanon. Eur J Contracept Reprod Health Care 2008; 13 Suppl 1:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/44\">",
"      Jensen JT. Contraceptive and therapeutic effects of the levonorgestrel intrauterine system: an overview. Obstet Gynecol Surv 2005; 60:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/45\">",
"      Sabatini R, Cagiano R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception 2006; 74:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/46\">",
"      Strufaldi R, Pompei LM, Steiner ML, et al. Effects of two combined hormonal contraceptives with the same composition and different doses on female sexual function and plasma androgen levels. Contraception 2010; 82:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/47\">",
"      Greco T, Graham CA, Bancroft J, et al. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol. Contraception 2007; 76:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/48\">",
"      Graham CA, Sherwin BB. The relationship between mood and sexuality in women using an oral contraceptive as a treatment for premenstrual symptoms. Psychoneuroendocrinology 1993; 18:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/49\">",
"      Caruso S, Agnello C, Intelisano G, et al. Prospective study on sexual behavior of women using 30 microg ethinylestradiol and 3 mg drospirenone oral contraceptive. Contraception 2005; 72:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/50\">",
"      Graham CA, Ramos R, Bancroft J, et al. The effects of steroidal contraceptives on the well-being and sexuality of women: a double-blind, placebo-controlled, two-centre study of combined and progestogen-only methods. Contraception 1995; 52:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/51\">",
"      Schaffir JA, Isley MM, Woodward M. Oral contraceptives vs injectable progestin in their effect on sexual behavior. Am J Obstet Gynecol 2010; 203:545.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/52\">",
"      Gallo MF, Lopez LM, Grimes DA, et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2011; :CD003987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/53\">",
"      Lindh I, Ellstr&ouml;m AA, Milsom I. The long-term influence of combined oral contraceptives on body weight. Hum Reprod 2011; 26:1917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/54\">",
"      Edelman A, Jensen JT, Bulechowsky M, Cameron J. Combined oral contraceptives and body weight: do oral contraceptives cause weight gain? A primate model. Hum Reprod 2011; 26:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/55\">",
"      Lopez LM, Edelman A, Chen-Mok M, et al. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev 2011; :CD008815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/56\">",
"      Bonny AE, Secic M, Cromer B. Early weight gain related to later weight gain in adolescents on depot medroxyprogesterone acetate. Obstet Gynecol 2011; 117:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/57\">",
"      Mishell DR Jr. Noncontraceptive health benefits of oral steroidal contraceptives. Am J Obstet Gynecol 1982; 142:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/58\">",
"      Kost K, Forrest JD, Harlap S. Comparing the health risks and benefits of contraceptive choices. Fam Plann Perspect 1991; 23:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/59\">",
"      French L. Dysmenorrhea. Am Fam Physician 2005; 71:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/60\">",
"      Yonkers KA, Brown C, Pearlstein TB, et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005; 106:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/61\">",
"      Dialogues in Contraception 3. Therapeutic uses of oral contraceptives 1991; 59:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/62\">",
"      ESHRE Capri Workshop Group. Noncontraceptive health benefits of combined oral contraception. Hum Reprod Update 2005; 11:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/63\">",
"      ACOG Practice Bulletin No. 110: noncontraceptive uses of hormonal contraceptives. Obstet Gynecol 2010; 115:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/64\">",
"      Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer 2006; 95:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/65\">",
"      Hannaford PC, Selvaraj S, Elliott AM, et al. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ 2007; 335:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/66\">",
"      Cullins VE. Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate. J Reprod Med 1996; 41:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/67\">",
"      Hubacher D, Grimes DA. Noncontraceptive health benefits of intrauterine devices: a systematic review. Obstet Gynecol Surv 2002; 57:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/68\">",
"      Hall KS, Trussell J, Schwarz EB. Progestin-only contraceptive pill use among women in the United States. Contraception 2012; 86:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/69\">",
"      Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception 2011; 84:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/70\">",
"      Rosenberg MJ, Waugh MS, Long S. Unintended pregnancies and use, misuse and discontinuation of oral contraceptives. J Reprod Med 1995; 40:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/71\">",
"      Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 2006; 38:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/72\">",
"      Peipert JF, Zhao Q, Allsworth JE, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol 2011; 117:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/73\">",
"      Lewis LN, Doherty DA, Hickey M, Skinner SR. Implanon as a contraceptive choice for teenage mothers: a comparison of contraceptive choices, acceptability and repeat pregnancy. Contraception 2010; 81:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/74\">",
"      Thurman AR, Hammond N, Brown HE, Roddy ME. Preventing repeat teen pregnancy: postpartum depot medroxyprogesterone acetate, oral contraceptive pills, or the patch? J Pediatr Adolesc Gynecol 2007; 20:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/75\">",
"      Hou MY, Hurwitz S, Kavanagh E, et al. Using daily text-message reminders to improve adherence with oral contraceptives: a randomized controlled trial. Obstet Gynecol 2010; 116:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/76\">",
"      Casta&ntilde;o PM, Bynum JY, Andr&eacute;s R, et al. Effect of daily text messages on oral contraceptive continuation: a randomized controlled trial. Obstet Gynecol 2012; 119:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/77\">",
"      Westhoff C, Heartwell S, Edwards S, et al. Initiation of oral contraceptives using a quick start compared with a conventional start: a randomized controlled trial. Obstet Gynecol 2007; 109:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/78\">",
"      Stewart FH, Harper CC, Ellertson CE, et al. Clinical breast and pelvic examination requirements for hormonal contraception: Current practice vs evidence. JAMA 2001; 285:2232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/79\">",
"      Foster DG, Parvataneni R, de Bocanegra HT, et al. Number of oral contraceptive pill packages dispensed, method continuation, and costs. Obstet Gynecol 2006; 108:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/80\">",
"      Foster DG, Hulett D, Bradsberry M, et al. Number of oral contraceptive pill packages dispensed and subsequent unintended pregnancies. Obstet Gynecol 2011; 117:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/81\">",
"      Potter JE, McKinnon S, Hopkins K, et al. Continuation of prescribed compared with over-the-counter oral contraceptives. Obstet Gynecol 2011; 117:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/82\">",
"      White KO, Westhoff C. The effect of pack supply on oral contraceptive pill continuation: a randomized controlled trial. Obstet Gynecol 2011; 118:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/83\">",
"      Upson K, Reed SD, Prager SW, Schiff MA. Factors associated with contraceptive nonuse among US women ages 35-44 years at risk of unwanted pregnancy. Contraception 2010; 81:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/84\">",
"      Weisman CS, Maccannon DS, Henderson JT, et al. Contraceptive counseling in managed care: preventing unintended pregnancy in adults. Womens Health Issues 2002; 12:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/85\">",
"      Lee JK, Parisi SM, Akers AY, et al. The impact of contraceptive counseling in primary care on contraceptive use. J Gen Intern Med 2011; 26:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/0/32777/abstract/86\">",
"      Halpern V, Lopez LM, Grimes DA, Gallo MF. Strategies to improve adherence and acceptability of hormonal methods of contraception. Cochrane Database Syst Rev 2011; :CD004317.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5484 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-CAE5397922-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_0_32777=[""].join("\n");
var outline_f32_0_32777=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BASIC INFORMATION ABOUT CONTRACEPTIVE CHOICES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34055285\">",
"      ASSESSING VALUES, PREFERENCES, AND GOALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MEDICAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34055928\">",
"      Pre-existing medical conditions and personal characteristics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35391008\">",
"      COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Information to guide counseling about the magnitude of thrombotic risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Risk of VTE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Risk of arterial events",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Effect of smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Information on counseling about side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4142766\">",
"      - Unscheduled bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4142687\">",
"      - Change in libido",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27702900\">",
"      - Change in weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Counseling about noncontraceptive benefits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      STRATEGIES FOR ENHANCING COMPLIANCE AND CONTINUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5484\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5484|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/13/12506\" title=\"table 1\">",
"      CDC Medical Eligibility Criteria for Contraceptive Use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/35/33339\" title=\"table 2\">",
"      Noncontraceptive benefits",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/8/4233?source=related_link\">",
"      Contraception counseling for obese women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26759?source=related_link\">",
"      Contraception for women with inherited thrombophilias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/45/34522?source=related_link\">",
"      Depot medroxyprogesterone acetate for contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/63/29690?source=related_link\">",
"      Drugs and the liver: Patterns of drug-induced liver injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37859?source=related_link\">",
"      Effect of oral contraceptives and postmenopausal hormone therapy on blood pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/10/22698?source=related_link\">",
"      Management of unscheduled bleeding in women using contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39306?source=related_link\">",
"      Overview of contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=related_link\">",
"      Overview of the use of estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/60/9157?source=related_link\">",
"      Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/17/18707?source=related_link\">",
"      Patient information: Hormonal birth control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/32/22021?source=related_link\">",
"      Patient information: Hormonal methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_0_32778="Doppler LA appendage flow during normal sinus rhythm";
var content_f32_0_32778=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54600%7ECARD%2F78275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54600%7ECARD%2F78275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Doppler interrogation of LA appendage flow during normal sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 528px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A diagram of left atrial appendage (LAA) flow in sinus rhythm. is shown on panel A; panel B shows the pulsed-Doppler tracing of LAA flow. Phases of LAA flow include LAA contraction (1); LAA filing (2); systolic reflection waves (positive and negative) (3); early diastolic LAA outflow (4).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from the American College of Cardiology (Journal of the American College of Cardiology, 1999, 34:1867-77.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.elsevier.com/locate/jacc\">",
"      file://www.elsevier.com/locate/jacc",
"     </a>",
"     <br/>",
"     <a href=\" file://www.sciencedirect.com\">",
"      file://www.sciencedirect.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Doppler interrogation of LA appendage flow during atrial fibrillation and atrial flutter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 415px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The pulsed-Doppler tracing of LAA flow in atrial fibrillation is seen in panel A. Note the rapid fibrillatory flow waves, which are of higher velocity during ventricular diastole than systole (arrows). Pulsed-Doppler tracing of LAA flow in atrial flutter (with a 2:1 ventricular response) is seen in panel B. Flutter flow waves are, in general, slower and of higher velocity than fibrillatory flow waves.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from the American College of Cardiology. Agmon, Y, Khandheria, BK, Gentile, F, Seward, JB. J Am Coll Cardio, 1999; 34:1867.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.elsevier.com/locate/jacc\">",
"      file://www.elsevier.com/locate/jacc",
"     </a>",
"     <br/>",
"     <a href=\" file://www.sciencedirect.com\">",
"      file://www.sciencedirect.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_0_32778=[""].join("\n");
var outline_f32_0_32778=null;
var title_f32_0_32779="Conventional approach to cardioversion";
var content_f32_0_32779=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Advantages and disadvantages of the conventional approach to cardioversion (one month of pretreatment with warfarin) in patients with atrial fibrillation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Advantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use of warfarin for one month before cardioversion may lower the stroke rate from 5.6 percent to a very low stroke rate of &lt;2 percent.",
"       </td>",
"       <td>",
"        Delaying cardioversion to normal sinus rhythm for one month potentially decreases functional capacity.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Relatively easy to administer with regular monitoring of INRs.",
"       </td>",
"       <td>",
"        Prolonging treatment for&nbsp;seven to&nbsp;eight weeks one month prior to and one month after cardioversion increases the risk of bleeding complications.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suitable for community hospitals.",
"       </td>",
"       <td>",
"        Not followed by routine clinical practice, especially in the elderly.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The conventional approach has withstood the \"test of time\" since the 1960s.",
"       </td>",
"       <td>",
"        Patients who are at the highest risk for developing systemic embolization who should receive more prolonged or intensive anticoagulation are not routinely identified.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from the American College of Cardiology. J Am Coll Cardiol 2001; 37:691.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.elsevier.com/locate/jacc\">",
"      file://www.elsevier.com/locate/jacc",
"     </a>",
"     <br/>",
"     <a href=\" file://www.sciencedirect.com\">",
"      file://www.sciencedirect.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_0_32779=[""].join("\n");
var outline_f32_0_32779=null;
var title_f32_0_32780="Drugs pneumococcal meningitis children";
var content_f32_0_32780=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antimicrobial therapy for bacterial meningitis in children caused by Streptococcus pneumoniae based upon susceptibility test results in patients begun on vancomycin and either cefotaxime or ceftriaxone",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Susceptibility test results*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antibiotic management",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Susceptible to penicillin",
"       </td>",
"       <td>",
"        <p>",
"         Discontinue vancomycin",
"        </p>",
"        <p>",
"         <strong>",
"          AND",
"         </strong>",
"        </p>",
"        <p>",
"         Begin penicillin (and discontinue cephalosporin)",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Continue cefotaxime or ceftriaxone alone",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         Not susceptible to penicillin (intermediate or resistant)",
"        </p>",
"        <p>",
"         <strong>",
"          AND",
"         </strong>",
"        </p>",
"        <p>",
"         Susceptible to cefotaxime and ceftriaxone",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Discontinue vancomycin",
"        </p>",
"        <p>",
"         <strong>",
"          AND",
"         </strong>",
"        </p>",
"        <p>",
"         Continue cefotaxime or ceftriaxone",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Not susceptible to penicillin (intermediate or resistant)",
"        </p>",
"        <p>",
"         <strong>",
"          AND",
"         </strong>",
"        </p>",
"        <p>",
"         Not susceptible to cefotaxime or ceftriaxone (intermediate or resistant)",
"        </p>",
"        <p>",
"         <strong>",
"          AND",
"         </strong>",
"        </p>",
"        <p>",
"         Susceptible to rifampin",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Continue vancomycin",
"         <strong>",
"          AND",
"         </strong>",
"        </p>",
"        <p>",
"         Either cefotaxime",
"         <strong>",
"          OR",
"         </strong>",
"         ceftriaxone",
"        </p>",
"        <p>",
"         Rifampin may be added in selected circumstances",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Based upon quantitative susceptibility studies.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      See text for doses.",
"      <br>",
"       &Delta; Some physicians may choose this alternative for convenience and cost savings.",
"       <br>",
"        <font class=\"lozenge\">",
"         &loz;",
"        </font>",
"        Addition of rifampin after 24 to 48 hours of therapy may be warranted if:",
"        <br>",
"         <ol>",
"          <li>",
"           Clinical condition worsens, or",
"          </li>",
"          <li>",
"           Gram stain or culture of repeat cerebrospinal fluid (CSF) indicates failure to substantially reduce bacterial number, or",
"          </li>",
"          <li>",
"           Cefotaxime or ceftriaxone minimum inhibitory concentration (MIC) of 4 mcg/mL or greater",
"          </li>",
"         </ol>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     From: American Academy of Pediatrics. Pneumococcal infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. Used with the permission of the American Academy of Pediatrics. Copyright &copy; 2012.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_0_32780=[""].join("\n");
var outline_f32_0_32780=null;
var title_f32_0_32781="Congenital toxoplasmosis initial evaluation";
var content_f32_0_32781=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Initial clinical evaluation of the newborn/infant with suspected congenital toxoplasmosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Clinical evaluations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Complete physical examination",
"       </td>",
"       <td>",
"        Fever, jaundice, hepatosplenomegaly, and lymphadenopathy are common findings in symptomatic infants (but the examination is normal in most cases)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Eye examination by ophthalmologist experienced in retinal examinations in newborn and young infants",
"       </td>",
"       <td>",
"        Chorioretinitis may be the only manifestation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neurologic examination including CT of the head without contrast",
"       </td>",
"       <td>",
"        Intracranial calcifications or hydrocephalus may be the only manifestation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hearing assessment",
"       </td>",
"       <td>",
"        Currently recommended for all infants (in the United States)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Lumbar puncture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CSF glucose, protein, cell count",
"       </td>",
"       <td>",
"        CSF abnormalities may be the only manifestation; CSF protein may be &gt;1 g/dL in severely affected infants but is typically lower in mild or subclinical disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Toxoplasma-specific PCR*",
"       </td>",
"       <td>",
"        Can establish the diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Primary serology*",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Toxoplasma-specific IgG (ELISA)",
"       </td>",
"       <td>",
"        Does not differentiate maternal from infant infection in the newborn period",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Toxoplasma-specific IgM (double sandwich ELISA)",
"       </td>",
"       <td>",
"        Indicative of congenital infection if not contaminated with maternal blood; negative IgM does not exclude congenital toxoplasmosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Additional serology*",
"        <sup>",
"         &bull;",
"        </sup>",
"        (complementary and more sensitive than primary serology)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Toxoplasma-specific IgA (ELISA/ISAGA)",
"       </td>",
"       <td>",
"        Indicative of congenital infection if not contaminated with maternal blood; especially useful if IgG and IgM assays are indeterminate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Toxoplasma-specific IgE (ELISA/ISAGA)",
"       </td>",
"       <td>",
"        Indicative of congenital infection if not contaminated with maternal blood; especially useful if IgG and IgM assays are indeterminate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Blood tests (primarily performed before initiating treatment in confirmed or suspected cases)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CBC with differential and platelet count",
"       </td>",
"       <td>",
"        Anemia and thrombocytopenia are common in symptomatic infants; also necessary to establish baseline before treatment, which may cause bone marrow suppression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Evaluation for G6PD deficiency (before initiation of treatment)",
"       </td>",
"       <td>",
"        Treatment with sulfadiazine may cause hemolysis in G6PD-deficient children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liver function tests (aspartate aminotransferase, alanine aminotransferase, total and direct bilirubin)",
"       </td>",
"       <td>",
"        Primarily for baseline studies before initiating treatment; both direct and cholestatic jaundice may occur in infected infants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum creatinine and urinalysis (before initiation of treatment)",
"       </td>",
"       <td>",
"        Sulfadiazine (or sulfamerazine or sulfamethazine) dosing requires adjustment in patients with renal insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Miscellaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urine for cytomegalovirus",
"       </td>",
"       <td>",
"        To exclude congenital cytomegalovirus, which may have similar clinical manifestations; coinfection with cytomegalovirus and toxoplasmosis may occur",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CT: computed tomography; CSF: cerebrospinal fluid; PCR: polymerase chain reaction; IgG: immunoglobulin G; ELISA: enzyme-linked immunosorbent assay; IgM: immunoglobulin M; IgA: immunoglobulin A; ISAGA: immunosorbent agglutination assay; IgE: immunoglobulin E; CBC: complete blood count; G6PD: glucose-6-phosphate-dehydrogenase.",
"     <br>",
"      * Performed or confirmed in a reference laboratory (eg, the Toxoplasmosis Serology Laboratory at the Palo Alto Medical Foundation Research Institute --",
"      <a href=\"file://www.pamf.org/serology\" target=\"_blank\">",
"       www.pamf.org/serology",
"      </a>",
"      ; the WHO/FAO International Centre for Research and Reference on Toxoplasmosis, Staten Serum Institute, Copenhagen, Denmark; the Toxoplasma Reference Laboratory, Public Health Laboratory, Singleton Hospital, Swansea, United Kingdom).",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       The same serologic tests should be performed on maternal serum; in addition, maternal serum should be obtained for differential agglutination test.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <br>",
"      <ol>",
"       <li>",
"        Remington JS, McLeod R, Wilson CB, Desmonts G. Toxoplasmosis. In: Infectious Diseases of the Fetus and Newborn Infant, 7th ed, Remington JS, Klein JO, Wilson CB, et al (Eds), Elsevier Saunders, Philadelphia 2011. p.918.",
"       </li>",
"       <li>",
"        Lynfield R, Ogunmodede F, Guerina NG. Toxoplasmosis. In: Oski's Pediatrics: Principles and Practice, 4th ed, McMillan JA, Feigin RD, DeAngelis CD, Jones MD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1351.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_0_32781=[""].join("\n");
var outline_f32_0_32781=null;
var title_f32_0_32782="Intravenous agents for pediatric procedural sedation";
var content_f32_0_32782=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Commonly used intravenous agents for pediatric procedural sedation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"10%\">",
"     </colgroup>",
"     <colgroup width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"6\">",
"        <strong>",
"         These agents should ONLY be administered by clinicians trained and experienced in pediatric procedural sedation using continuous non-invasive electronic monitoring of oxygenation, heart rate and blood pressure. End-tidal carbon dioxide monitoring is also suggested. Resuscitation equipment, medications, and personnel skilled in advanced pediatric life support and knowledgeable of sedatives and reversal agents must be present. Please refer to UpToDate topics on procedural sedation in children for more details.",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Initial intravenous dose*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Repeat intravenous dose (as needed to achieve desired level of sedation)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Onset (minute)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration (minutes)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Ketamine",
"       </td>",
"       <td>",
"        <p>",
"         1 to 1.5 mg/kg",
"        </p>",
"        <p>",
"         when given with propofol, reduce initial dose to 0.5 mg/kg",
"        </p>",
"       </td>",
"       <td>",
"        0.5 to 1 mg/kg repeat every 10 minutes titrating to desired level of sedation",
"       </td>",
"       <td>",
"        1 to 2",
"       </td>",
"       <td>",
"        15 to 30",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Provides sedation AND analgesia for moderately to severely painful procedures. Less respiratory depression and complications than propofol alone or combinations of opioids with midazolam or with propofol.",
"         </li>",
"         <li>",
"          Common adverse events: Vomiting, emergence reaction, frequency of vomiting is reduced by premedication with ondansetron (0.15 mg/kg, typical dose 4 mg) or by co-administration of propofol",
"         </li>",
"         <li>",
"          Laryngospasm and apnea occur rarely and are more common with intramuscular administration",
"         </li>",
"         <li>",
"          Relative contraindications and precautions: Age younger than 12 months, active pulmonary infections (including URI), known or suspected cardiac disease, suspected increased intracranial pressure (eg, head trauma with signs or symptoms, intracranial mass, or hydrocephalus), glaucoma or acute eye injury (open globe), porphyria, thyroid disease",
"         </li>",
"         <li>",
"          Absolute contraindications: Age younger than 3 months or patients with known or suspected psychosis",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Midazolam",
"       </td>",
"       <td>",
"        <p>",
"         6 months&nbsp;to 5 years: 0.05 to 0.1 mg/kg IV, maximum single dose 2 mg&nbsp;",
"        </p>",
"        <p>",
"         6 to 12 years: 0.025 to 0.05 mg/kg IV, maximum single dose 2 mg",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         After initial IV dose, repeat after 2 to 5 minutes titrating to desired level of sedation",
"        </p>",
"        <p>",
"         6 months&nbsp;to 5 years: up to 0.2 mg/kg per dose (maximum total dose 6 mg),",
"        </p>",
"        <p>",
"         6 to 12 years: 0.1 mg/kg (maximum total dose 10 mg)",
"        </p>",
"       </td>",
"       <td>",
"        1 to 3",
"       </td>",
"       <td>",
"        15 to 60, depending upon total dose administered",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Provides sedation but NO analgesia. For painful procedures, an analgesic agent (eg, ketamine, fentanyl) should be co-administered.",
"         </li>",
"         <li>",
"          Provides amnesia, mild anxiolysis, and mild sedation for procedures that do not require full immobility (eg, laceration repair with local topical anesthesia)",
"         </li>",
"         <li>",
"          When combined with fentanyl can produce moderate or deep sedation, but less effective and more adverse respiratory events reported when compared to sedation with ketamine alone or combined with propofol",
"         </li>",
"         <li>",
"          Flumazenil can reverse effects but should be avoided in patients with seizure disorder or who are chronically maintained on benzodiazepines",
"         </li>",
"         <li>",
"          Common adverse effects: Respiratory depression, and apnea, especially when combined with opioid medications (eg, fentanyl); paradoxical reactions, including hyperactivity, aggressive behavior, and inconsolable crying",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Propofol",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Initiate infusion at 25 mcg/kg per minute and titrate gradually to response (range 50 to 200 mcg/kg per minute)",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"        <p>",
"         OR",
"        </p>",
"        <p>",
"         0.5 to 1 mg/kg IV bolus dose (children two years of age and older)",
"        </p>",
"        <p>",
"         1 to 2 mg/kg IV bolus dose (infants 6 months to 2 years of age)",
"        </p>",
"        Significant dose reduction necessary for patients who are debilitated or with reduced cardiac output",
"       </td>",
"       <td>",
"        <p>",
"         Not applicable for continuous IV infusion, titrate infusion rate as needed",
"        </p>",
"        <p>",
"         OR",
"        </p>",
"        Additional IV bolus dose 0.5 mg/kg every 3 to 5 minutes titrating as needed up to 3 mg/kg. Wait at least 3 to 5 minutes between doses to assess effect.",
"       </td>",
"       <td>",
"        &le;0.5",
"       </td>",
"       <td>",
"        5 to 15 after single bolus dose, longer after prolonged infusion or when repeated bolus doses are given",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Provides sedation but NO analgesia. For painful procedures, an analgesic agent (eg, ketamine, fentanyl) should be co-administered. Commonly used for diagnostic imaging (CT, MRI).",
"         </li>",
"         <li>",
"          Rapid onset of sedation with good neurologic recovery. Reduces intracranial pressure.",
"         </li>",
"         <li>",
"          Peripheral injection site pain",
"          <sup>",
"           &Delta;",
"          </sup>",
"         </li>",
"         <li>",
"          Common adverse events: Respiratory depression, oxygen desaturation, apnea, hypotension, and/or rapid transition to deeper levels of sedation, especially with overly rapid administration of bolus injection",
"         </li>",
"         <li>",
"          Absolute contraindications: Egg or soy allergy, porphyria",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Dexmedetomidine",
"       </td>",
"       <td>",
"        <p>",
"         1 to 3 mcg/kg loading dose (over 10 minutes) followed by 0.5 to&nbsp;2 mcg/kg per",
"         <strong>",
"          hour",
"         </strong>",
"         continuous infusion",
"        </p>",
"        Children younger than 5 years of age may require maintenance infusion rates at the higher end of the range shown",
"       </td>",
"       <td>",
"        Not applicable for continuous infusion, titrate infusion rate as needed",
"       </td>",
"       <td>",
"        5 to 10",
"       </td>",
"       <td>",
"        30 to 70",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Sedation and modest analgesia without respiratory depression. Commonly used for diagnostic imaging (CT, MRI).",
"         </li>",
"         <li>",
"          Common adverse events: Bradycardia, hypertension, or, especially with loading dose, hypotension",
"         </li>",
"         <li>",
"          Relative contraindications: Children who are debilitated, inadequately hydrated, or have reduced cardiac output",
"         </li>",
"         <li>",
"          Absolute contraindication: Patients receiving digoxin or other medications acting on sinus node or with sinus node dysfunction",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Pentobarbital",
"       </td>",
"       <td>",
"        <p>",
"         1 to 2 mg/kg IV, maximum 100 mg per dose",
"        </p>",
"       </td>",
"       <td>",
"        1 to 2 mg/kg IV every 3 to 5 minutes titrate up to 6 mg/kg to desired sedation",
"       </td>",
"       <td>",
"        1&nbsp;to 5",
"       </td>",
"       <td>",
"        15&nbsp;to 90, duration is dose dependent",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Short-acting barbiturate option for noninvasive diagnostic procedures. Better efficacy seen in children &lt;8 years old.",
"         </li>",
"         <li>",
"          Common adverse effects: Respiratory depression, hypotension, and increased heart rate, especially with intravenous use or combination with opioid or benzodiazepine, emergence reactions",
"         </li>",
"         <li>",
"          Relatively contraindicated in patients with cardiac or hepatic insufficiency or hypovolemic shock",
"         </li>",
"         <li>",
"          Absolute contraindications: Porphyria",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Etomidate",
"       </td>",
"       <td>",
"        <p>",
"         0.1 to 0.3 mg/kg IV",
"        </p>",
"        Lower dose in children with renal or hepatic insufficiency",
"       </td>",
"       <td>",
"        0.05 mg/kg every 3 to 5 minutes titrate up to 0.6 mg/kg total dose to desired sedation",
"       </td>",
"       <td>",
"        &le;0.5",
"       </td>",
"       <td>",
"        5 to 15",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Rapid onset and recovery. Commonly used for brief diagnostic imaging (eg, head CT).",
"         </li>",
"         <li>",
"          Reduces intracranial pressure. Hemodynamic and respiratory stability maintained in most patients making it a good choice if cardiovascular status is unknown or compromised (eg, trauma patient).",
"         </li>",
"         <li>",
"          Common adverse effects: Pain at the injection site, transient nonepileptiform myoclonus, vomiting. Myoclonus and vomiting reduced by premedication with midazolam.",
"         </li>",
"         <li>",
"          Relatively contraindicated in children with severe illness such as suspected sepsis",
"         </li>",
"         <li>",
"          Absolutely contraindications: Children with congenital or acquired adrenal insufficiency",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methohexital",
"       </td>",
"       <td>",
"        0.5 to 1 mg/kg IV",
"       </td>",
"       <td>",
"        0.5 mg/kg IV (maximum 40 mg per dose)every 2 to 5 minutes, titrate&nbsp;up to 2 mg/kg (160 mg total dose)",
"       </td>",
"       <td>",
"        0.5 to 1",
"       </td>",
"       <td>",
"        5 to 10",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Short-acting barbiturate option for noninvasive diagnostic procedures. More adverse events than pentobarbital.",
"         </li>",
"         <li>",
"          Common adverse effects: Respiratory depression, hypotension, and myocardial depression",
"         </li>",
"         <li>",
"          Relative contraindications: Patients with cardiac, liver, or renal insufficiency",
"         </li>",
"         <li>",
"          Absolute contraindications: Porphyria or partial seizure disorder (may precipitate seizures)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Doses are given as a suggested range for the initial dose. Children may differ markedly with respect to efficacy of any single dose and careful titration to effect by using repetitive dosing to achieve the desired depth and duration of sedation is necessary for any individual patient. Suggested initial doses should be reduced &asymp; fifty percent for patients who are debilitated or with reduced cardiac output. These medications do not provide analgesia.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      In some institutions, propofol is ONLY approved for use by anesthesiologists or others with specialized pediatric procedural sedation training. Otherwise, propofol use for procedural sedation in children may be unlicensed. Check local policies.",
"      <br>",
"       &Delta; Some providers start the propofol infusion at a higher rate (eg, 100 mcg/kg per minute) because few children will be adequately sedated at lower infusion rates.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_0_32782=[""].join("\n");
var outline_f32_0_32782=null;
var title_f32_0_32783="Occiput transverse position";
var content_f32_0_32783=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Occiput transverse positions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 189px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Right occiput transverse (ROT), (B) Left occiput transverse (LOT).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_0_32783=[""].join("\n");
var outline_f32_0_32783=null;
